Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel®, on the Ocular Surface of Ophthalmological and Clinically Healthy Subjects.
Phase: PHASE1
Conditions: Dry Eye, Dry Eye Syndrome of Unspecified Lacrimal Gland
Sponsor: Laboratorios Sophia S.A de C.V.

CONFIDENTIAL 
 
  
 
 
 
 
Creation date: August 2016 
Phase I clinical study, to evaluate the safety and 
tolerability of the ophthalmic gel PRO-167 versus 
Corneregel® 
on 
the 
ocular 
surface 
of 
ophthalmological and clinically healthy subjects 
Protocol code: SOPH167-0816 / I 
Protocol version: 1.0 
Date of the version: 08/08/2016 
Registration: 173301410A0062/2017 
Sponsor: Sophia Laboratories, S.A. de C.V.  
 

 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 1 of 65 
 
1. Summary 
Title of the study: 
Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic gel PRO-167 versus 
Corneregel®, on the ocular surface of ophthalmological and clinically healthy subjects.  
Protocol code: 
SOPH167-0816/I 
Creation date: 
08/08/2016 
Protocol version: 
1.0 
Date of the version: 
08/08/2016 
Therapeutic indication: 
Reepithelizing of the corneal surface 
Study period:  
3 to 4 months 
Development phase: I 
Goals: 
To evaluate the safety and tolerability of the ophthalmic gel PRO-167 manufactured by Sophia 
Laboratories S.A. of C.V. on the ocular surface of clinically healthy subjects. 
Hypothesis: 
Ophthalmic gel PRO-167 has a safety and tolerability profile similar to that of its comparator in 
healthy subjects. 
Methodology: 
Phase I clinical trial, controlled, of parallel groups, double blind, randomized, exploratory. 
Number of patients: 
24 subjects, divided into 2 groups [12 eyes exposed per group] 
Diagnosis and main inclusion criteria: 
- 
Systemically and ophthalmologically healthy subjects. 
- 
Signed informed consent. 
- 
Age between 18 to 45 years. 
- 
Both genders. 
- 
Blood tests [complete blood count (BHc), three element blood chemistry (QS) and liver 
function tests (PFH)] within normal parameters. 
- 
Visual capacity 20/30 or better. 
Test product, dose and route of administration, lot number: 
- PRO-167. Dexpanthenol 5%. Ophthalmic gel produced by Sophia Laboratories A.S. of V.C., 
Zapopan, Jalisco, Mexico. 
- Dose: a strip approximately 1 cm long, 4 times a day during the period of 
vigil, in the bottom of the right eye sac. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 2 of 65 
 
- Route of administration: ophtalmic. 
Duration of treatment: 10 days 
Reference product, dose and route of administration, lot: 
- Corneregel®. Dexpanthenol 5%. Ophthalmic gel developed by Bausch & Lomb, Berlin, Germany. 
▪ 
 Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in 
the bottom of the right eye sac. 
▪ 
 Route of administration: ophthalmic 
Evaluation criteria: 
  
- 
Density of goblet cells. 
- 
Epithelial defects in cornea and conjunctiva. 
- 
Presence of adverse events. 
Secondary outcome variables: 
- 
Intraocular pressure. 
- 
Visual ability 
- 
Break time of the tear film. 
- 
Laboratory tests: BHc, QS and PFH. 
- 
Ophthalmological signs: conjunctival hyperemia, chemosis. 
- 
Life signs: FC, FR, TAS. 
- 
Subsequent segment. 
- 
Quality questionnaire. 
Primary outcome variables of tolerability: 
- 
Burning. 
- 
Foreign body sensation. 
- 
Itching. 
- 
Eye comfort index. 
Statistical methodology: 
The data will be expressed with measures of central tendency: mean and standard deviation for 
the quantitative variables. The qualitative variables will be presented in frequencies and 
percentages. The statistical analysis will be carried out through the Mann-Whitney U-test for 
quantitative variables. The difference between the qualitative variables will be analyzed by means 
of X2 (Chi2). An alpha ≤ 0.05 will be considered significant. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 3 of 65 
 
2. Content 
1. SUMMARY 
1 
2. CONTENT 
3 
3. INDEX OF ABBREVIATIONS 
7 
4. ADMNISTRATIVE STRUCTURE OF THE STUDY 
9 
5. INTRODUCTION 
11 
5.1 THEORETICAL FRAMEWORK 
11 
5.2 DEFINITION OF THE PROBLEM AND FUNDAMENTAL REASON 
¡ERROR! MARCADOR NO DEFINIDO. 
5.3 BACKGROUND 
¡ERROR! MARCADOR NO DEFINIDO. 
5.3.1 DEXPANTENOL 5 % 
16 
5.3.1.1 Eyeball pharmacokinetics 
16 
5.4 JUSTIFICATION 
17 
5.5 OBJETIVES AND HYPOTHESIS 
17 
5.5.1 GENERAL OBJECTIVE 
¡ERROR! MARCADOR NO DEFINIDO. 
5.5.2 SPECIFIC OBJETIVES 
¡ERROR! MARCADOR NO DEFINIDO. 
5.5.3 HYPOTHESIS 
18 
5.6 STUDY DESIGN AND PLAN 
18 
5.6.1 DISCUSSION OF THE STUDY DESIGN 
18 
6. MATERIAL AND METHODS, PARTICIPANTS, INTERVENTIONS AND VARIABLES 
19 
6.1 STUDY CENTER 
19 
6.1.1 ORGANIZATION OF THE CENTER 
19 
6.1.2 DOCUMENTATION TO BE DELIVERED TO SPONSOR 
19 
6.1.3 CLOSURE OF CENTER 
20 
6.2 ELEGIBILITY CRITERIA 
20 
6.2.1 INCLUSION CRITERIA 
¡ERROR! MARCADOR NO DEFINIDO. 
6.2.2 EXCLUSION CRITERIA 
20 
6.2.2.1 General criteria 
20 
6.2.2.2 Medical and therapeutic criteria 
21 
6.2.3 ELIMINATION CRITERIA 
21 
6.2.4 IDENTIFICATION OF SUBJECT 
21 
6.3 INTERVENTION 
22 
6.3.1 ADMINISTERED TREATMENTS 
¡ERROR! MARCADOR NO DEFINIDO. 
6.3.1.1 Treatment under study 
¡Error! Marcador no definido. 
6.3.1.2 Reference treatment 
22 
6.3.2 STRATEGIES TO IMPROVE ADHERENCE AND PROCEDURE TO MONITOR ADHERENCE 
22 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 4 of 65 
 
6.3.2.1 Procedure to monitor adherence 
23 
6.3.3 TREATMENTS AND COMMITTED INTERVENTIONS ALLOWED AND PROHIBITED DURING THE STUDY 
24 
6.3.4 MANAGEMENT OF TREATMENT 
24 
6.3.4.1 Delivery and reception 
24 
6.3.4.2 Storage 
24 
6.3.4.3 Return 
25 
6.4 OUTCOME VARIABLES 
25 
6.4.1 SEGURITY VARIABLES 
¡ERROR! MARCADOR NO DEFINIDO. 
6.4.1.1 Primary outcome variables 
¡Error! Marcador no definido. 
6.4.1.2 Variables of primary outcome of tolerability 
25 
6.4.1.3 secondary outcome variables 
25 
6.4.2 EFFECTIVENESS VARIABLES 
25 
6.4.2.1 Primary outcome variables 
¡Error! Marcador no definido. 
6.4.2.2 Secondary outcome varibles 
25 
6.4.3 METHODS AND SCALES TO BE USED FOR THE MEASUREMENT OF VARIALES 
26 
6.4.3.1 visual capacity 
29 
6.4.3.2 Globet cell density (Cytology per impression) 
29 
6.4.3.3 Eye comfort index 
30 
6.4.3.4 Integrity of ocular surface: conjunctival hyperemia and chemosis 
31 
6.4.3.5 Presence of adverse events 
31 
6.4.3.6 Intraocular pressure 
31 
6.4.3.7 Posterior segment 
31 
6.4.3.8 Vital signs 
32 
6.4.3.9 Ocular symptomatology 
32 
6.4.3.10 Rupture time of the tear film 
32 
6.4.3.11 Pregnancy test 
¡Error! Marcador no definido. 
6.4.3.12 Laboratory test 
33 
6.4.4 TIME OF MEASUREMENTS 
33 
6.5 CHRONOGRAM AND STUDY DIAGRAM 
¡ERROR! MARCADOR NO DEFINIDO. 
6.5.1 PROCEDURES TO BE CARRIED OUT BY VISIT 
36 
6.5.1.1 Scrutiny visit 
36 
6.5.1.2 Basal visit 
36 
6.5.1.3 Visit 1 
37 
6.5.1.4 Final Visit 
37 
6.5.1.5 Security call 
38 
6.5.2 STUDY DIAGRAM 
38 
6.6 SAMPLE SIZE 
38 
6.6.1 CALCULATION OF SAMPLE SIZE 
38 
6.7 RECRUITMENT 
39 
7. METHODS, ASSIGNMENT OF THE INTERVENTION 
39 
7.1 GENERATION OF THE ASSIGNMENT SEQUENCE 
39 
7.2 BLINDING MECHANISM 
39 
7.3 IMPLEMENTATION 
40 
7.4 BLINDING (MASKNG) 
40 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 5 of 65 
 
7.4.1 BLIND OPENING 
40 
8. METHODS, COLLECTION, ADMINISTRATION AND DATA ANALYSIS 
40 
8.1 METHODS OF DATA COLLECTION 
40 
8.1.1 STRATEGIES TO COMPLETE FOLLOW-UP 
41 
8.2 ADMINISTRATION OF DATA 
41 
8.3 STATISTICAL METHODOLOGY 
42 
8.3.1 ANALYSIS OF PRIMARY AND SECONDARY DISSOLVEMENT VARIABLES 
42 
8.3.2 ADDITIONAL ANALYSIS 
42 
8.3.3 POPULATION ANALYSIS AND HANDLING OF MISLEADING DATA 
43 
9. METHODS. MONITORING 
43 
9.1 DATA MONITORING 
43 
9.2 PRELIMINARY ANALYSIS AND EARLY TERMINATION OF THE STUDY 
44 
9.3 ADVERSE EVENTS 
45 
9.3.1 RESPONSIBILITIES OF THE INVESTIGATOR 
45 
9.3.1.1 Record of adverse events in the Case Report Form 
45 
9.3.1.2 Follow up of adverse events 
46 
9.3.1.3 Procedures for a serious adverse event 
46 
9.3.1.4 Evaluation of causality 
48 
9.3.2 SPONSORSHIP RESPONSIBILITIES 
50 
9.4 AUDIT 
50 
9.4.1 AUDIT PRIOR TO STUDY 
50 
9.4.2 AUDIT / INSPECTION DURING THE DRIVING OF THE STUDY 
50 
10. ETHICAL CONSIDERATIONS 
50 
10.1 APPROVAL OF THE COMMITTEES 
50 
10.2 AMENDMENTS TO THE PROTOCOL 
51 
10.3 INFORMED CONSENT 
52 
10.3.1 OBTAINMENT 
52 
10.3.2 SPECIAL CONSIDERATIONS 
53 
10.3.3 MODIFICATION TO INFORMED CONSENT 
53 
10.4 CONFIDENTIALITY 
53 
10.5 DESVIATIONS 
53 
10.5.1 MANAGEMENT OF DESVIATIONS 
54 
10.6 DECLARATION OF INTEREST 
55 
10.7 ACCESS TO INFORMATION 
55 
10.8 AUXILARY CARE AND SUBSEQUENT TO THE COMPLETION OF THE STUDY 
55 
10.9 BIOSECURITY ASPECTS 
55 
10.10  FINAL REPORT AND PUBLICATION OF RESULTS 
55 
10.10.1 FINAL REPORT 
55 
10.10.2 COMUNICATION OF RESULTS 
55 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 6 of 65 
 
10.10.3 PUBLICATION OF RESULTS 
55 
11. BIBLIOGRAPHIC  REFERENCES 
56 
12. SIGNATURE PAGE 
61 
13. ANEXES 
63 
13.1 EYE CONFORT INDEX 
63 
13.2 EFRON SCALE FOR CONJUNCTIVE HYPEREMIA 
65 
13.3 OXFORD SCALE 
65 
 
 
Index of tables and figures 
 
Table 1. Administrative structure ....................................................... ¡Error! Marcador no definido. 
Table 2. Cells, molecules, factors and cytokines involved incorneal repair¡Error! 
Marcador 
no 
definido. 
Table 3. Quali-quantitative formulation of PRO-167 ......................... ¡Error! Marcador no definido. 
Table 4. Scales to be used ................................................................... ¡Error! Marcador no definido. 
Table 5. Nelson Classification .............................................................. ¡Error! Marcador no definido. 
Table 6. Algorithm of Karch and Lasagna modified by Naranjo ........ ¡Error! Marcador no definido. 
 
Figure 1 Minimum organization of the center.................................... ¡Error! Marcador no definido. 
Figure 2. Study diagram .................................................................................................................... 38 
Figure 3. Attention to the adverse event ........................................... ¡Error! Marcador no definido. 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 7 of 65 
 
3. Index of abbreviations 
 
ALT  
Alanino transferase 
AST  
Aspartate transferase 
BAK  
Benzalkonium chloride, (for its acronym in English Benzalkonium chloride.) 
BD  
Direct bilirubin 
BI  
Indirect bilirubin 
BHc  
Complete blood count 
BPC  
Good clinical practices 
BT  
Total Bilirubin 
CV  
Visual capacity 
CCI  
informed consent letter 
CIC  
Cytology by conjunctival impression 
IEC  
Research Ethics Committee 
CI  
Informed Consent 
CRF  
Case Report Form (Case Report Form) 
EA/EAS Adverse event / serious adverse event 
FDA  
Food and Drug Administration (Food and Drug Administration) 
FC  
Heart rate 
FR  
Respiratory frequency 
ICH  
International Conference on Harmonization (for its acronym in English International 
Conference on Harmonization) 
ICO  
Eye comfort index 
IP  
Principal investigator of the clinical study 
PFH  
Liver function tests 
IOP  
intraocular pressure 
TAS  
Systemic blood pressure 
TF  
Fluorescein staining 
TVL  
Green lysine stain 
QS  
Blood chemistry 
 
 
 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 8 of 65 
 
 
 
 Page left intentionally blank

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 9 of 65 
 
4. Administrative structure of the study 
The administrative structure of the sponsoring party, corresponding to Sophia Laboratories A.S. of 
V.C. is shown in Table 1. Administrative structure 
Function 
Name/ Contact 
Afilliation ¥ 
Medical responsible 
for the study 
Dr. Leopoldo Martín Baiza Durán 
leopoldo.baiza@sophia.com.mx 
Medical Director and Regulatory Affairs 
Director of the study 
Dr. Aldo Arturo Oregón Miranda 
aldo.oregon@sophia.com.mx 
Clinical Operations Manager 
Scientific Comittee 
Dr. Oscar Olvera Montaño 
oscar.olvera@sophia.com.mx 
Ophthalmologist Investigator 
Scientific Comittee 
Dr. en C. Arieh Roldán Mercado Sesma 
arieh.mercado@sophia.com.mx 
Biostatist 
Scientific Comittee 
Dr. en C. Ricardo Alonso Llamas Velázquez 
ricardo.llamas@sophia.com.mx  
Clinical pharmacologist 
Coordinator of 
regulatory 
procedures 
LN. Ana Isabel Alcaraz Ledón 
ana.alcaraz@sophia.com.mx 
Specialist in the beginning of clinical 
studies 
Monitoring 
coordinator 
QFB Virginia Manuela Villa Félix 
virgina.villa@sophia.com.mx 
Monitor coordinator 
International 
monitor 
M. en F. Sandra Carolina Gómez Méndez 
sandra.gomez@sophia.com.mx 
Senior Monitor 
Monitor 
QFB Jessica Lizette Mejía Gutiérrez 
jessica.mejia@sophia.com.mx 
Senior Monitor 
Monitor 
LP María Angela González Ávila 
maria.gonzalez@sophia.com.mx 
Junior Monitor 
Monitor 
QFB Lizeth de Jesús Pérez Lerma 
lizeth.perez@sophia.com.mx 
Junior Monitor 
Monitor 
LN Pilar Carolina Castro Mata 
pilar.castro@sophia.com.mx 
Junior Monitor 
Administrative 
Assistant 
LAET Maira Alejandra Ramírez Velazco 
alejandra.ramirez@sophia.com.mx 
Clinical Operations Assistant 
¥ Employees of Sophia Laboratories, S.A. of C.V Av. Paseo del Norte No.5255, Col. Guadalajara 
Technology Park, Carretera Guadalajara-Nogales Km13.5 C.P45010 Zapopan, Jalisco, Mexico Tel +52 
(33) 3000 4200 
Table 1. Administrative structure 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 10 of 65 
 
 
 Page left intentionally blank

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 11 of 65 
 
5. Introduction 
5.1 Theoretical framework 
1. The cornea has a fundamental role in the optics of vision. It has physiological and 
histopathological characteristics that no other tissue possesses: it is avascular, it is 
considered the most sensitive tissue, it is transparent and curved to achieve an optimal 
refraction of light. 
2. These special characteristics are due to the cellular organization and strict regulation of the 
aqueous content. The cornea is formed by three types of cells: 
3. Epithelial. 
4. Stroms. 
5. Endothelial. 
The epithelial cells comprise the outermost layer. Its main function is to serve as a barrier between 
the external world and the internal environment. This cellular group is formed by a well-defined 
laminar structure from the basement membrane and outwardly by basal cells, winged cells and 
superficial cells, respectively. On the other hand, the components of the corneal stroma include: 
type I and IV, laminin and fibronectin. [1] [2] 
The turnover of epithelial cells is estimated between 1-2 weeks, however, only the cells of the basal 
layer have mitotic activity. The stability and dynamics of the corneal epithelium is maintained by 
three processes: 1) proliferation of basal epithelial cells; 2) centripetal movement of the cells of the 
periphery and 3) desquamation or loss of the outer epithelial cells. [1] In addition, of these 
mechanisms, the stem cells in the limbus region are complemented by epithelial cells. When the 
stem cells of the limbus are deficient, the epithelial cells are unable to cover the defects, this causes 
the conjunctival cells to migrate to the cornea. A process that is accompanied, in addition to 
neovascularization. [1] [3]  
Cell-cell and cell-substrate adhesion is maintained by integrins α5β1, α5 and β4. In addition there 
are two types of contact in cell adhesion, union adhesions and non-union adhesions, which 
participate in the structure and repair of the corneal epithelium. [1] [4] In turn, there are 4 types of 
union accessions: a) gap junctions; b) zonula occludens (tight junctions); c) desmosomes; and d) 
zonula adherens. [1] On the other hand, non-union adhesions use integrins and specific ligands such 
as the intercellular adhesion molecule-1 (ICAM-1, for its acronym in English intercellular adhesion 
molecule-1). All these components maintain the integrity of the corneal epithelium, coupled with a 
complex signaling through integrins, cytokines, growth factors and nerve stimuli. [1] [2] [5] 
Repair of corneal wounds 
Corneal wounds are all those disruptions in the continuity of some of the strata that make up the 
corneal tissue. They are due to constant or abrupt traumas, elective or not, for example, refractive 
surgeries. [6] [7] Damage to the corneal epithelium leads to the formation of edema, the activation 
of fibroblasts, and the infiltration of inflammatory cells into the stroma. This response derives in the 
loss of transparency and integrity of the cornea. Nevertheless, these changes in integrity activate 
repair mechanisms to restore homeostasis and function. [2] [1] [8] 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 12 of 65 
 
The process in the repair of epithelial wounds includes three mechanisms which are grouped into 
two phases: 
1. Initial phase: it is characterized by a cellular and subcellular rearrangement. Its objective is to 
initiate the migration of epithelial cells to edge of the wound. During this phase there is no mitotic 
activity. 
2. Closing phase: involves cell proliferation and differentiation. Some authors mention that the 
stratification of the epithelial layers is part of this phase. [2]  
Unlike the skin, the corneal epithelium does not undergo keratinization during differentiation. It is 
essential that the cell-cell adhesion be re-established before the epithelium begins its barrier 
function. During these phases they participate directly and indirectly, in a cascade of orchestrally 
organized signaling, multiple cells, cytokines, molecules (peptides or proteins in their majority), 
receptors and factors that promote the precise repair of the corneal tissue. [1] [2] See Table 1. 
This intricate molecular pathway has points of pharmacological interest, which are being explored 
to promote or inhibit this physiological process. [9] 
Molecule 
Function 
EGF, Epidermal growth factor 
Start the migration and proliferation. Activates the NF-κB pathway. 
HGF, Hepatocyte growth factor 
Stimulates epithelial cells. Activates P38-MAP. 
Promotes the expression of markers for stem cells. 
KGF, Keratinocyte growth factor 
It acts on limbic cells. Increases proliferation of the limbal epithelium by 
MAP kinases, PI3K, P70S6. 
IGF, Insulin-like growth factor 
Stimulates cell differentiation in the limbus. 
TGF-β, Transforming growth 
factor 
Stimulates the proliferation of stromal fibroblasts. 
Increase the repair speed. 
TGF-β1 and 2 have antagonistic effects to EGF, HGF and KGF in vitro 
PDGF, Platelet-derived growth 
factor 
Regulate the migration and proliferation of keratocytes in the presence 
of fibronectin 
NGF, Nerve growth factor 
Modulates DNA synthesis, migration and tissue organization. Inhibits 
proliferation 
OGF, Opioid growth factor 
Modulate migration. Modulates the differentiation of keratocytes. 
Stimulates migration in epithelial and stromal cells. 
Tβ4, Thymosin- β4 
Promotes re-epithelialization Decreases inflammation It inhibits 
apoptosis. It protects corneal endothelial cells from UV radiation and 
oxidative stress. 
IL-6 y 10, interleukin-6, 10 
Improve migration 
P2Y-P2X, Purinergic receptors 
Participates in the migration by means of the rearrangement of actin in 
the cytoskeleton 
TLRH, Toll-like receptor 
Improves migration and proliferation. Modulates inflammation through 
NF-κB, MAP, AP-1 
ROCK, Rho-associated protein 
cinase 
Participate in differentiation, proliferation. It also participates in the 
reorganization of the cytoskeleton cell-cell and cell-matrix adhesion 
NF, 
nuclear 
factor, 
MAP, 
mitogen-activated 
protein, 
PI3K, 
phosphatidylinositol-3-kinase, 
ADN, 
ácido 
desoxirribonucleico, AP-1, activator protein-1.  
Table 2. Cells, molecules, factors and cytokines involved in corneal repair 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 13 of 65 
 
 
Corneal alterations: ulcers and abrasions 
Any alteration in the morphological and histopathological structure of the cornea modifies its 
function. Ulcers and abrasions are among the most common defects, which can progress to 
permanent tissue damage and consequently transient or permanent visual defects. [10] [11] 
Corneal abrasions are histological disruptions that affect only epithelial cells. In contrast, in ulcers, 
the stromal layer is also affected. The etiology is diverse and involves mechanical, chemical, 
infectious and intrinsic agents, in a general way. The severity will depend on the time of exposure 
to the etiologic factor, the characteristics of this, the cell layers affected and the time in which the 
treatment is granted. [12] [13] Nevertheless, once the damage occurs, an immune response is 
initiated to repair the damage in order to recover the function and histological characteristics of the 
cornea. 
The treatment currently available for corneal injuries can be divided into: 
1. Doctor 
a) Antibiotics: tetracycline, doxycycline, minocycline. 
b) Tissue inhibitor of MMP, ilomastat. 
c) Steroids 
d) Autologous serum 
e) Lubricants: dexpanthenol. 
f) Growth factors: FGF, EFG. 
g) Ascorbic acid and citrate. 
h) Immunomodulators. 
            2. Surgical 
According to Tuli et al, [7] all corneal ulcers, except those in which the etiology is an autoimmune 
disease, should be treated with lubricants. 
The main objective in the care of patients with corneal injuries is to recover the morphology of the 
cellular strata and maintain function. 
Eye lubricants are a safe, accessible, inexpensive and easy to use option, in most cases. They allow 
the recovery of the corneal surface with a low risk of serious adverse events. In addition, they are a 
minimally invasive therapy that can be combined with other types of therapies.  
 
 5.2 Definition of the problem and fundamental reason 
Corneal lesions (ulcers and abrasions) are common pathologies, according to a WHO report in 2001 
in the countries of emerging economies, which in a large percentage are treated by doctors not 
ophthalmologists. [14] [15] Although in its majority, the evolution is not catastrophic, it is important 
to determine the etiology and give a timely treatment, since it is estimated that the average cost of 
care is 600 dollars, in the case of uncomplicated ulcers. [16] Nevertheless, the true impact occurs 
when the treatment is not timely and appropriate, because the complications usually end in 
blindness. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 14 of 65 
 
The ideal treatment should be according to the etiology and severity, nevertheless, it is important 
that it can be used concomitantly with other therapies, that it is low cost, with a low rate of adverse 
events, easily accessible and that it can be used easily by health teams and patients.  
The use of dexpanthenol in the repair of wounds is a feasible option in relation to ease of use and 
cost in the Mexican population. According to its participation in the inflammatory process 
establishing relationships with molecules (TGF, EGF) and cells (fibroblasts, epithelium), it has 
therapeutic advantages, which would increase treatment options. [17] 
5.3 Background 
In Mexico there are no exact data on the presentation of corneal lesions. Notwithstanding, 
worldwide, an incidence of corneal lesions (ulcers and abrasions) is estimated at between 1.5 and 2 
million of the population per year. [18] Coupled with a high cost of treatment, these alterations pose 
a challenge for the health systems of any country. However, the most significant impact lies in the 
complications that may arise if the treatment is not timely and adequate. 
The repair of corneal tissue is a complex and orderly process, where multiple molecules and cells of 
the immune system interact with the different cellular strata of the cornea. During this signaling 
network it is possible to identify key points, which can be modified pharmacologically, in order to 
accelerate, improve or inhibit the repair response. 
Dexpanthenol (vitamin B5) has been widely used in the cosmetic industry in products for the skin, 
hair, mucous membranes and eyes. Its main application route is topical. [19] In Ophthalmology, it 
has been used as an ocular lubricant due to its hygroscopic properties. 
In a randomized, controlled clinical trial conducted in Germany, the efficacy and tolerance of a gel 
versus a dexpanthenol ointment was evaluated. The study population (n = 48) was composed of 
patients with corneal erosions, keratoconjunctivitis due to UV radiation or similar corneal 
conditions. The intervention consisted in the administration of 1 cm of the gel and the ointment 4 
and 3 times a day for 14 days, respectively. Corneal erosion staging was performed (≤ 10%,> 10 but 
<25%, ≥25 but ≤ 50%,> 50%), subjective symptoms were evaluated with an ordinal scale (0 = non-
existent, 1 = minimum, 2 = moderate, 3 = intense) and objective symptoms (conjunctival injection, 
ciliary injection, photophobia, lacrimation, blepharospasm, edema-corneal opacity and epithelial 
defects, on days 0, 3, 8 and 14. 
In the evaluation of day 3, 50 vs 45% of the subjects, of the group with gel and ointment, presented 
corneal erosions less than 10% with reference to the basal size, respectively. At the final visit, all the 
erosions were less than 10% of the size, in both groups, with a tendency to be faster in the decrease 
in size in the gel group. Regarding the symptoms, they were reported non-existent in both groups 
during the final evaluation. Tolerance was reported as very good by the patients. However, in the 
group with ointment there was a higher incidence of alterations in vision, compared with the gel 
group. [20]  
In 1996, Martin Göbbels and Dorothea Groβ, published the results of a double-blind, controlled, 
randomized clinical trial conducted in 50 subjects with dry eye, divided into two groups, which were 
administered five drops per day of tears artificial with and without dexpanthenol for 6 weeks. The 
outcome variables were measured before and after the intervention. Corneal permeability was 
evaluated by means of fluorophotometry and the Schirmer test. In addition, staining with Bengal 
rose and lacrimal rupture time was performed. All subjects made a subjective evaluation of 
complaints (tolerability). 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 15 of 65 
 
 
After 6 weeks of intervention, the epithelial permeability of the cornea was better, in the group with 
dexpanthenol, compared to the other group. The other parameters did not show differences. [21]  
In another double blind, randomized clinical trial, the efficacy of a dexpanthenol plus vitamin A 
ointment and a gel based on a hemodialysis free of calf blood proteins was evaluated and compared. 
We included 54 subjects with superficial corneal lesions due to foreign metallic bodies. After the 
removal of the foreign body and the debris, an exploration of the anterior segment with a slit lamp 
was performed. The depth of the corneal lesion was classified (superficial, medium and deep) and 
the percentage of damaged area was calculated by planimetry. The intervention consisted in the 
application, single dose, of the gel with dexpanthenol + vitamin A or the hemodialysis in the 
conjunctival cul-de-sac. Subsequently, the eye was bandaged. The control review was performed 24 
hours later and, if necessary, during the following days. Healing was defined as a reduction of the 
initial corneal injury in less than 5% of the total. 
No statistical difference was observed between the groups 24 hours after the intervention. 
Nevertheless, 81.3% of the subjects who used the gel with dexpanthenol + vitamin A showed healing 
in corneal lesions of 1-6 mm2. In those lesions of 7 - 26 mm2, the greatest recovery appeared on 
day 2 (72%). [22]  
Raczynska et al, made a comparison between a gel and a solution (drops) of dexpanthenol, using as 
a model conjunctival and corneal lesions in the postoperative period. The groups were conformed 
by 40 eyes, which received the active intervention and the placebo. Among the reported results it 
is mentioned that from the second day, after the surgery, an improvement was observed in the 
repair of the lesion (disappearance of the edema and conjunctival congestion), in the group that 
received dexpanthenol. In addition, the edges of the wound improved and the tendency to close. 
[2. 3]  
In that same year (2003), the group from the University of Gdańsk (Poland) evaluated a 
dexpanthenol gel placed, during the examination of the retina, on the contact surface of a three-
lens Goldmann-type lens. The sample size was 84 eyes, divided according to the intervention: 
dexpanthenol exploration group (n = 42) and exploration group with 3% methylcellulose (n = 42). 
The ophthalmological variables to be evaluated were conjunctival congestion, edema and defects 
of the corneal epithelium. In addition, the transparency of the molecules under investigation was 
evaluated. The result showed less congestion of the conjunctiva and a greater facility to perform 
the exploration procedure with the use of dexpanthenol compared to the group with 
methylcellulose. [24]  
Smolle et al. Developed a randomized clinical trial in 92 subjects undergoing elective surgery under 
general anesthesia. The objective was to compare the perioperative ocular comfort and in vitro 
bacterial growth of a 0.2% carbomero hydrogel against a dexpanthenol and vitamin A ointment. The 
intervention consisted in the application of 40 mg ointment (n = 46) and instillation of two hydrogel 
drops (n = 46) after anesthesia. 
The ocular comfort was evaluated using an ordinal scale ("yes", "rather yes", "rather no", "no") by 
means of a questionnaire which contained the following reagents: burning sensation / itching, dry 
eye , foreign body sensation, blurred vision and perception. An ophthalmological examination was 
performed to identify conjunctival inflammation (lacrimation, hyperemia), palpebral adhesion 
(difficulty to open the eyelids before a verbal command) and palpebral edema.  The bacterial growth 
was evaluated, after the inoculation of 10 mL of S. aureus (10 2 bacteria for 14 hours at 37 ° C) in 1 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 16 of 65 
 
gram of the hydrogel and the ointment (incubation for 24 hours), by means of the number of 
forming units of colonies (UFC). 
After the surgery none of the participants presented corneal abrasions. There were no significant 
differences between the groups in relation to the sensation of burning, itching and dry eyes. The 
patients who received the ointment reported a greater presence in the sensation of foreign body, 
blurred vision and palpebral adherence compared with those who received the hydrogel solution (p 
<0.001). In relation to bacterial growth, the hydrogel group presented 17 CFU more compared with 
ointment and control. [25]  
Reepithelialization and complete restoration of the superficial layer of the corneal epithelium was 
achieved between day 7 and 14. In the cases of severe epitheliopathies, the repair was not 
complete. [26] 
5.3.1 Dexpanthenol 5 % 
It is a component of animal tissues. It participates in the synthesis of fatty acids, porphyrins and 
acetylcholine, in the release of ATP from carbohydrates. It is also part of the degradation of fatty 
acids, sterols and steroid hormones. It is an essential component in food. [19] 
In ophthalmology it is classified as a lubricant, due to its properties in water retention. The 
pharmaceutical forms in which it is marketed are: gel, ointment and solution. [27] [28] [29] 
Its pharmacological effect in the repair of wounds, is due to several mechanisms: 
1) Conversion into pantothenic acid, a component of coenzyme A, which participates in the 
metabolism of epithelial cells. [30] 
2) Increase in the gene expression of cytokines, mainly IL-6 that participates in 
reepithelialization, granulation and wound closure. [30] 
3) Promotes the proliferation and migration of fibroblasts. [17] 
4) Increase in gene expression of CCR-1 (chemokine receptor-1, chemokine receptor-1) 
which promotes the migration of macrophages and neutrophils in the area of the wound. 
[17] 
5) Increase in MCP-1 (Monocyte chemotactic protein-1, for its acronym in English, monocyte 
chemotactic protein-1). [17] 
6) Increase in TGF-B. [17] 
7) Increase antioxidant levels (reduced glutathione, coenzyme A). [31] [32] 
 
5.3.1.1 Eyeball pharmacokinetics 
 
Route of administration: topical-ophthalmic. 
Release: immediate. 
 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 17 of 65 
 
 
 
Absorption: no absorption of dexpanthenol has been reported through any ocular tissue or through 
the epithelium of the skin into the systemic circulation. [19] 
Metabolism: It is not described in ophthalmology. Systemically, dexpanthenol is degraded in 
pantothenic acid, due to enzymatic oxidation, in the liver. In the eye, metabolism is likely to occur 
at the corneal level, without allowing absorption by cytochrome enzymes located in this region 
(CYP1B1, CYP2A6, CYP2C8, CYP2D6, CYPE1, CYP3A4, CYP4B1, CYP4V2). [19] [33] [34] 
Elimination: Occurs with the kinetics of the flicker and dissolved in the tear film. 
There are no data on the area under the curve, Cmax, T1 / 2. 
5.4 Justification 
The risk of developing a corneal lesion increases in the population that is of productive age, due to 
the use of instruments, tools, machines and substances typical of work activity. Nevertheless, those 
patients undergoing surgery with prolonged times in the procedure are also at risk. In addition to 
the characteristics of the corneal tissue, as the ocular layer that has contact with the environment 
and its repair mechanisms. 
The severity of the injury will depend on the etiology and treatment. Nevertheless, the cost of care 
and the complications that can be triggered make corneal injuries a challenge for doctors and health 
systems. 
The treatment of corneal lesions (erosions and ulcers) should be timely, effective, easily accessible, 
economically available and according to the etiology. In most cases, the first treatment option 
should be pharmacological management (lubricants), within which there is a wide variety of 
medications. 
Dexpanthenol as a lubricant or ocular reepititelizer has demonstrated its efficacy and safety in the 
healing of the corneal epithelium in different clinical situations. It is a well tolerated option, easily 
accessible and that can be used in most corneal injuries, regardless of the etiology.  
According to its pharmacological properties, its absorption is almost null and its metabolism is wide, 
it can be used several times a day without the risk of developing serious adverse events. Its 
pharmacodynamics allows it to act by different mechanisms and interact with the various molecules 
in the repair of the cell layers that make up the cornea. 
  According to the pharmacological development and the design of the present protocol, the PRO-
167 molecule is a formulation which requires the documentation of its safety profile. 
 
5.5 Objectives and hypothesis 
5.5.1 General Objective 
To evaluate the safety and tolerability of the ophthalmic gel PRO-167 on the ocular surface. 
5.5.2 Specific objectives 
 
Describe the safety of the ophthalmic gel PRO-167 by means of the density of goblet cells 
 
Describe the safety of the ophthalmic gel PRO-167 by means of changes in ocular surface 
stains. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 18 of 65 
 
 
 
- Describe the safety of the ophthalmic gel PRO-167 by means of changes in intraocular pressure. 
- Describe the safety of the ophthalmic gel PRO-167 by means of changes in laboratory tests. 
- Describe the safety of the ophthalmic gel PRO-167 by means of changes in vital signs. 
- Describe the safety of the ophthalmic gel PRO-167 by means of changes in visual ability. 
- Describe the safety of the ophthalmic gel PRO-167 by means of changes in the time of tear rupture. 
- Describe the safety of the ophthalmic gel PRO-167 by means of changes in the ocular comfort 
index. 
- Describe the safety of the ophthalmic gel PRO-167 by means of changes in the posterior segment. 
- Describe the safety of the ophthalmic gel PRO-167 by means of changes in ophthalmological signs 
and symptoms. 
- Describe the safety of the ophthalmic gel PRO-167 when assessing the integrity of the anterior 
segment by means of the green lysine stain. 
- Describe the safety of the ophthalmic gel PRO-167 by means of the presentation of adverse events. 
 
 
5.5.3 Hypothesis 
 
Ha Ophthalmic gel PRO-167 presents a safety and tolerability profile similar to the comparator in 
healthy subjects. 
Ho Ophthalmic gel PRO-167 presents a safety and tolerability profile different from the comparator 
in healthy subjects. 
5.6 Design and plan of the study 
Clinical trial, phase I, controlled, parallel groups, double blind randomization, exploratory. 
 
5.6.1 Discussion of the study design 
The design of the study (clinical trial) is considered the highest quality standard in the data when it 
is sought to explore the effect of an intervention. The phase of pharmacological development (phase 
I) corresponds to the objective of the study which is to assess safety and tolerability, so that the 
intervention time is short and the sample size required is less than that of a clinical efficacy trial. The 
presence of parallel groups allows the comparison between the intervention groups on the outcome 
variables. Blinding and randomization allows to reduce biases that are incurred with other designs, 
e.g. Selection bias, evaluation bias, among others. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 19 of 65 
 
6. Material and methods. Participants, interventions and variables 
6.1 Study Center 
The present study will be performed in ophthalmology offices duly equipped and registered for their 
proper functioning. According to the needs of the sponsor, these may be private or public, be 
attached to a hospital or clinic or be independent. 
6.1.1 Organization of the center 
Each study center will have a principal investigator (PI). The PI is the ophthalmology specialist in the 
clinical study.  
The PI is responsible for forming a multidisciplinary research team to carry out the clinical study 
according to protocol, under its scientific guidance. It is the prerogative of the IP the design of the 
organization of its center and the selection of the personnel that will perform the functions. 
However, the minimum organization of the research team requested by the sponsor requires the 
figure of sub-researcher, study coordinator and pharmacist. (See Figure 1 Minimum organization 
of the center) 
Any person to whom the PI designates, under his / her responsibility, a part of the follow-up of the 
study (co-investigator, under-researcher, nurse, etc.) or a specific function of participation in the 
study (pharmacist, administrative assistant, study coordinator, etc.) should appear in the 
"Delegation of Responsibilities" format. 
 
 
 
 
 
 
Figure 1 Minimum organization of the center 
 
The "Delegation of Responsibilities" and the "Organizational Chart of the Center" must be delivered 
to the sponsor before the start of the study and updated if the members or their responsibilities are 
changed. 
6.1.2 Documentation to be delivered to the sponsor 
The PI must deliver to the sponsor, before the start of the study: 
- Curriculum vitae updated, in Spanish, dated and signed (maximum 10 pages), of the IP and the 
staff that integrates its organizational chart of the center. 
- Copy of IP academic certifications (degree certificate and specialty diploma in ophthalmology, 
federal professional certificates) 
- Copy of academic certifications of the maximum degree obtained, from each one of the members 
of your research team, that cover their capacity to perform the delegated functions. 
Principal 
investigator
Subinvestigator
Pharmacist
Study 
Coordinator

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 20 of 65 
 
- Copy of operating notice or similar issued by corresponding regulatory entity (When applicable) 
- Certificate of good clinical practice in force. If the issuing institution does not specify the validity 
period in the certificate, the date of issue of the certificate must not exceed one year 
6.1.3  Closure of the center 
The closing of the center will be carried out once the last visit of the last included subject previously 
agreed between the sponsor and the IP has been made. The closing process will be according to the 
internal operating procedures of the sponsor. 
It is the prerogative of the sponsor to prematurely close a study center, it must inform the IP the 
reasons for the closure. 
6.2 Eligibility criteria 
6.2.1 Inclusion criteria 
- 
Signed informed consent. 
- 
Systemically and ophthalmologically healthy subjects evaluated during the clinical history. 
- 
Age between 18 to 45 years. 
- 
Both genders. 
- 
Blood tests [complete blood count (BHc), three element blood chemistry (QS) and liver 
function tests (PFH)] within normal parameters specified by the reference laboratory with 
a lower and upper margin of 10%. 
- 
Vital signs within normal parameters. 
- 
Visual capacity 20/30 or better, in both eyes. 
- 
Intraocular pressure ≥11 and ≤ 21 mmHg. 
6.2.2 Exclusion criteria 
6.2.2.1 General criteria 
 
- Subjects with a history of hypersensitivity to any of the components of the research products. 
- Subject users of topical ophthalmic medications of any pharmacological group. 
- Subject users of medication by any other route of administration. 
- Pregnant or lactating women. 
- Women without a history of hysterectomy, oophorectomy, who do not ensure a hormonal 
contraceptive method or intrauterine device during the study period. 
- Subjects with participation in clinical research studies 90 days prior to inclusion in the present 
study. 
- Diagnosis of liver disease or elevation to three times the normal upper value of any of the following 
liver enzymes: aspartate transferase (AST), alanine transferase (ALT) or bilirubin. 
- Inability to attend or answer the evaluations made in each of the visits. 
- Positive smoking (specified as cigarette consumption regardless of amount and frequency) 
- Positive alcoholism (specified as the consumption of alcoholic beverages, regardless of quantity 
and frequency, during the study intervention period). 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 21 of 65 
 
- Contact lens users. 
6.2.2.2 Medical and therapeutic criteria 
6.2.3 Elimination criteria 
 
Withdrawal of the consent letter under information. 
 
Presentation of a serious adverse event. 
 
No tolerability or hypersensitivity to any of the compounds used during the tests 
(fluorescein, green lysine, tetracaine) 
 
No tolerability or hypersensitivity to any of the investigational drugs. 
 
Adherence <50% determined by the diary of the subject. 
6.2.4 Identification of the subject 
 The patients of the study will be identified by a number and the initials of their name. 
The initials of the study subject will be obtained starting with the first letter of the name, followed 
by the first letter of the first surname and the first letter of the second surname, obtaining maximum 
three letters, in case the person has two names or a compound surname the first letter will always 
be used. 
Example: 
1. Arieh Daniel Mercado Carrizalez 
a. Initials: AMC 
2. Juan De la Torre Orozco 
a. Initials: JDO 
In the counting stage, the participant number will be assigned consecutively, using 3 consecutive 
digits. Once the subject has been selected, he will be assigned a number with which he will be 
identified throughout the study. Said code will be integrated with eight numbers in the following 
order from left to right: 
• 
three digits of the molecule under study according to the denomination by the sponsor. 
• 
two digits corresponding to the research center number. 
• 
three digits of the number consecutive to its inclusion assigned in the research center. 
 
 
Example: 
 
 
 
 
167-01-001 
 Key of the 
molecule 
Center number 
Inclusion 
number 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 22 of 65 
 
6.3 Intervention 
6.3.1 Managed treatments 
6.3.1.1 Treatment under study 
  -         PRO-167  
o Active ingredients: Dexpanthenol 5% 
o Pharmaceutical form: Ophthalmic gel. 
o Prepared by: Sophia Laboratories A.S. of V.C. 
o Posology: a strip approximately 1 cm long, 4 times a day during the waking period, 
in the bottom of the right eye sac. 
o Description of the formulation: transparent gel, free of visible particles. 
o Description of the packaging: sterile multi-dose tube, low density polyethylene 
polyethylene and aluminum with high density polyethylene lid. 
Table 3. Quali-quantitative formulation of PRO-167 
Type of agent 
Amount mg/mL 
Function 
Dexpanthenol 
50.0 
Active principle (lubricant) 
Boric acid 
2.00 
Active principle 
Sodium Borate decahydrate 
without showing 
additive 
Polysorbate 80 
without showing 
additive 
Sorbitol 
without showing 
additive 
Potassium chloride 
without showing 
additive 
Sodium chloride 
without showing 
additive 
Magnesium Chloride hexahydrate 
without showing 
additive 
Water 
for 
the 
preparation 
of 
injectables c.b.p. 
1.00 
Vehicle 
Quali-quantitative formulation of the product under investigation PRO-167. The concentration of the active principles 
is shown, as well as the substances that act as a buffer additive. 
 
6.3.1.2 Reference treatment 
- 
Corneregel® 
o Active ingredients: Dexpanthenol 5% 
o Pharmaceutical form: Ophthalmic gel 
o Prepared by: Bausch & Lomb. 
o Posology: a strip approximately 1 cm long, 4 times a day during the waking period, 
in the bottom of the right eye sac. 
o Description of container: sterile multi-dose tuve 
o  
6.3.2 Strategies to improve adherence and procedure to monitor adherence 
 
1. Each visit the research subject will return the assigned tube in order to evaluate the 
adherence by weigh 
2. Direct questioning by the PI about the application of the intervention.  

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 23 of 65 
 
3. At the discretion of the IP, messages may be sent or reminder calls made. 
4. Delivery of a printed chronogram specifying the date of the visit and its activities 
5. Journal of the subject. 
6.3.2.1 Procedure to monitor adherence 
Before delivering the medication to the research subject, the pharmacist must weigh the tubes to 
be delivered. After the return of the medication by the subject will also carry out the weighing. 
Guidelines to follow for weighing: 
o The pharmacist will use the scale provided by the sponsor 
o Place the tube in the center of the balance. You will get the result of the measurement. 
o It will remove the tube from the balance and put it back, confirming that the measurement 
is the same. If it is different, it will weigh one more time and take the average of the 3 measurements 
o Record the result in the log and the CRF provided by the sponsor  
Adherence to the intervention will be calculated considering: the weight of the empty tube, the 
weight of the strip, the weight of the tube with the content, the calculation of the total gel to be 
applied during the entire intervention time and the total weight of the applied gel . The following 
simplified formula will be used: 
𝐴𝑑= (𝑃𝑖−𝑃𝑓)100
𝑃𝑇
 
Where: 
Ad = adhesion 
𝑃𝑖 = weight of the tube delivered to the subject at the start 
𝑃𝑓 = weight of the tube returned by the subject 
𝑃𝑇 = weight of the posology indicated for the intervention 
 
𝑃𝑇= (𝑃𝑔)𝐺 
where: 
𝑃𝑔= weight of a 1 cm strip of the intervention, determined by the research and development 
department 
G = number of applications indicated for the intervention 
Adherence will be estimated at each visit where the research subject returns the intervention. Only 
tubes without apparent physical damage will be considered for the calculation. This result will allow 
the PI to determine if the subject continues in the study according to the stipulations of the 
elimination criteria. 
The evaluation of the adherence by means of the diary of the subject will be carried out in the 
following way: 
𝐴𝑑= (𝐴𝑟)100/𝐴𝑖 
Ad = Adhesion 
Ar = Registered applications 
Ai = Applications indicated for the intervention 
The final (overall) adhesion will be determined by the average of the adherence of each of the visits. 
It will not be considered for the calculation of final adherence if the subject did not return the tube 
in two subsequent visits. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 24 of 65 
 
The balance will be provided by Sophia Laboratories, S.A de C.V. You must take shelter in a locked 
place. It will be placed on a smooth surface (table), avoiding the movement and the change of place 
as much as possible. The surface of the balance must be kept clean. The maintenance of the same 
must be according to the manufacturer's specifications. Its use is exclusive for protocol procedures. 
It is the IP's responsibility to safeguard and correct use. 
6.3.3 Treatments and concomitant interventions allowed and prohibited during the study 
The use of concomitant medications by any route of administration during the intervention period 
will not be allowed. Except those specified for the study procedures. The objective of this restriction 
is to avoid pharmacological interactions that could alter the results of the evaluated variables. 
6.3.4 Treatment management 
The interventions will be provided by Sophia Laboratories A.S. of V.C., for each research center. They 
will be labeled, reconciled and weighed previously. The handling of the treatment will be under the 
responsibility of the investigator or a designated member of his team. 
6.3.4.1 Delivery and reception 
The delivery will be made in closed cardboard boxes by means of a courier service or directly by the 
sponsor's staff to the address of the research center according to the study plan. 
The reception will be exclusively carried out by the research center team, including the researcher. 
You must check the good condition of the primary packaging (box). In the event that it shows 
alterations or defects in its integrity that from its judgment could have damaged the content, it 
should report it to the sponsor. If the package does not show significant defects, it will proceed to 
open it. 
Inside you must locate the acknowledgment document and the logger (data logger) of temperature 
and humidity. You should check that the registered temperature and humidity comply with the 
specifications for transport and shelter (see section 6.3.4.2 Storage). Verify the content 
(interventions) with what is reported in the document. In case the document corresponds to the 
content, it will sign the receipt and send it to the sponsor. Otherwise, notify the sponsor. 
In the study center, the personnel assigned by the PI will deliver the corresponding treatment to the 
subjects admitted, sufficient for the period to be covered. Delivery will be made in stages, 
medication will be delivered at the baseline visit and visit 1. The center must register the medicine 
delivered 
6.3.4.2 Storage 
 
The medication must be stored in a secure area with restricted access. 
 
The storage temperature should be at room temperature to no more than 25º Celsius. 
 
The research center has the obligation to record, in the format designated by the sponsor, the 
temperature and humidity registered in the data logger. This record should include the current 
temperature and humidity, as well as the minimum and maximum of each of these. It must be done 
at least once a day, on business days. 
Said data will be compared by the clinical monitor according to the registration in the data logger. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 25 of 65 
 
6.3.4.3 Return 
The research subjects will return to the staff indicated by the IP in the center their treatments in 
visits 1 and final. The refund will be made by the research center when the sponsor indicates it. Prior 
to the return the research center must make a count of the assigned medication and the remaining 
medication, with the aim of creating an inventory which serves for the final filling of the return form 
of the medication. 
6.4 Outcome variables 
6.4.1 Security variables 
6.4.1.1 Primary outcome variables 
 
 
Globet cell density 
 
Epithelial defects in cornea and conjunctiva. 
 
Presence of adverse events. 
6.4.1.2 Primary outcome variables of tolerability 
 
 
Burning 
 
Foreign body sensation 
 
Itching 
 
Eye comfort index 
6.4.1.3 Secondary outcome variables 
 
 
Intraocular pressure 
 
Visual ability 
 
Laboratory tests: BHc, QS and PFH. 
 
Ophthalmological signs: conjunctival hyperemia, chemosis. 
 
Rupture time of the tear film 
 
Life signs: FC, FR, TAS. 
 
Subsequent segment 
 
Quality questionnaire 
6.4.2 Efficacy variables 
6.4.2.1 Primary outcome variables 
 
It does not apply because it is a phase I study 
6.4.2.2 Secondary outcome variables 
 
It does not apply because it is a phase I study 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 26 of 65 
 
6.4.3 Methods and scales to be used for the measurement of the variables 
Variable 
Unit 
Symbolo 
Type 
Method of 
measurement 
Normal value 
Age 
 
years 
-- 
Continuous 
Calculation from the 
day of birth 
NA 
Gender 
Female/ Male 
F / M 
Nominal 
Direct questioning 
NA 
Adverse events 
Number of cases 
n 
Discreet 
Conteo 
NA 
Intraocular presure 
Milimeters of 
mercury 
mmHg 
Continuous 
Goldman´s 
applanation 
tonometry 
11 - 21 
Visual ability 
Fraction 
Snellen 
Nominal 
Chart 
 
Tear rupture time 
Seconds 
s 
Continuous 
Direct counting 
> 10   
Eye confort index 
Points 
-- 
Discreet 
Questioning 
 
Adverse events 
Present / Absent 
-- 
Nominal 
Comprehensive 
assessment 
Absent 
Goblet cell density 
Cells per square 
milimeter 
Cel/mm2 
Continuous 
Citology per 
impression 
> 500 cell/mm2 
Vital signs 
Heart rate 
Beats per minute 
lpm 
Discreet 
Auscultation 
60 – 100 
Breathing 
frequency 
Breaths per 
minute 
rpm 
Discreet 
Auscultation 
12 – 24 
Systemic blood 
pressure 
Milimeters of 
mercury 
mmHg 
Continuous 
Non-invasive 
auscultatory 
measurement 
< 120 / 80 
anterior segment 
 
Epithelial defects 
Degrees 
-- 
Discreet 
Direct observation 
with green lysine and 
fluorescein stains 
Oxford Scale 
Ophthalmologic signs and symptoms 
 
Conjunctival 
hiperemia 
 
Normal / Very 
Light / Mild / 
Moderate / 
Severe 
-- 
Ordinal 
Direct observation. 
  Classification of Efron 
Normal 
Chemosis 
 
Present / Away 
-- 
Nominal 
Direct observation 
Absent 
Burning 
Severity: Absent, 
very mild, mild, 
-- 
Nominal 
Direct questioning 
Absent 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 27 of 65 
 
Variable 
Unit 
Symbolo 
Type 
Method of 
measurement 
Normal value 
moderate and 
severe 
  Frequency: At all 
times, almost at 
all times, 50% of 
the time, almost 
in no time, at any 
time.  
Foreign body 
sensation 
Severity: Absent, 
very mild, mild, 
moderate and 
severe 
Frequency: At all 
times, almost at 
all times, 50% of 
the time, almost 
in no time, at any 
time 
-- 
Nominal 
Direct questioning 
Absent 
Pruritus 
Severity: Absent, 
very mild, mild, 
moderate and 
severe 
Frequency: At all 
times, almost at 
all times, 50% of 
the time, almost 
in no time, at any 
time 
-- 
Nominal 
Direct questioning 
Absent 
Post-application symptoms 
Burning 
Present / Away 
-- 
Nominal 
Journal of the subject 
Absent 
Sensación de 
cuerpo extraño 
Present / Away 
-- 
Nominal 
Journal of the subject 
Absent 
Prurito 
Present / Away 
-- 
Nominal 
Journal of the subject 
Absent 
Ojo rojo (síntoma) 
Present / Away 
-- 
Nominal 
Journal of the subject 
Absent 
posterior segment 
Macula 
Normal / 
Abnormal 
-- 
Nominal 
Direct observation 
Normal 
Optical disk 
integrity 
Normal / 
Abnormal 
-- 
Nominal 
Direct observation 
Normal 
Blood count 
Erythrocytes 
 
M/uL 
Continuous 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 28 of 65 
 
Variable 
Unit 
Symbolo 
Type 
Method of 
measurement 
Normal value 
Hemoglobin 
Grams over 
deciliter 
g/dL 
Continuous 
 
 
Hematocrit 
Porcentage 
% 
Continuous 
 
 
VGM 
Femto liters 
fL 
Continuous 
 
 
HCM 
picograms 
pg 
Continuous 
 
 
CMHbG 
Grams over 
deciliter 
g/dL 
Continuous 
 
 
Leukocytes 
Thousands per 
liter units 
Mil/uL 
Continuous 
 
 
Platelets 
Thousands per 
liter units 
Mil/uL 
Continuous 
 
 
Myelocytos 
Porcentage 
% 
Discreet 
 
 
Metamyelocytos 
Porcentage 
% 
Discreet 
 
 
Bands 
Porcentage 
% 
Discreet 
 
 
Segmented 
Porcentage 
% 
Discreet 
 
 
Lymphocytes 
Porcentage 
% 
Discreet 
 
 
Monocytes 
Porcentage 
% 
Discreet 
 
 
Eosinophils 
Porcentage 
% 
Discreet 
 
 
Basophils 
Porcentage 
% 
Discretet 
 
 
Blastos 
Porcentage 
% 
Discreet 
 
 
Blood chemistry 
Glucose 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 
Urea 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 
Creatinine 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 
Liver function tests 
Alanine transferase 
Units on liter 
U/L 
Continuous 
 
 
Aspartate 
transferase 
Units on liter 
U/L 
Continuous 
 
 
Total Bilirrubin 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 
Direct Bilirrubin 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 29 of 65 
 
Variable 
Unit 
Symbolo 
Type 
Method of 
measurement 
Normal value 
Indirect Bilirrubin 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 
Table 4. Scales to be used 
The following describes the methods and scales that will be used to measure the variables, which 
are in strict alphabetical order: 
6.4.3.1 Visual ability 
Visual acuity (VA) is a test of visual function. Spatial visual acuity is the ability to distinguish separate 
elements of an object and identify them as a whole. It is quantified as the minimum separation angle 
(located at the nodal point of the eye) between two objects that allows perceiving them as separate 
objects. 
Snellen's notation is described as the distance at which the test is performed, divided by the distance 
at which the letter is vertically equivalent to 5 arc minutes. Thus, at 6 meters a letter 6/6 (20/20) 
equals 5 minutes of arc, a letter 6/12 (20/40) equals 10 minutes, and a letter 6/60 (20/200) equals 
50 minutes The Snellen fraction can also be expressed as a decimal (ie 20/20 = 1 and 20/40 = 0.5). 
[38] 
The VA will be evaluated basally, without refractive correction with the Snellen chart. Which will be 
located in a place with adequate lighting, natural or artificial and at a distance of 3m from the subject 
to be evaluated. The visual acuity of each eye will be taken, starting with a right eye (DO) asking the 
subject to keep both eyes open and using an occluder to cover the left eye (OS); the subject will 
read aloud the lines that the evaluator points out, the line of smaller letters that he reaches to see 
will be annotated by the fractional evaluator as the DO of the DO in the clinical record. Proceed to 
the OS with the same method. 
Subsequently the best refractive correction of the subject will be made and the examination will be 
repeated using the obtained refraction. This result will be reported as CV, it will be written in fraction 
in the clinical file and in the CRF, in addition in the CRF it will be written in decimal. By definition, 
the CV can not be inferior to the AV. 
 
6.4.3.2 Goblet cell density (Cytology per impression) 
The density of goblet cells in the conjunctiva can be a reflection of the severity of alteration in the 
ocular surface. [39] It has been determined that the normal density is greater than 500 cel / mm2. 
[40] Impression cytology refers to the application of a cellulose acetate filter to the ocular surface 
to remove the superficial layers of the epithelium; these removed cells can be subjected to 
histological, immunohistological or molecular analysis. [41] 
The cytology per impression of the conjunctiva will be done by the researcher using the device 
provided by the sponsor for this purpose, which may consist of a circular cell of approximately 10 
mm in diameter, with a cellulose acetate filter millicell. After ocular surface anesthesia, with topical 
tetracaine, the researcher will ask the subject to expose the temporal surface of the eye to be 
evaluated and gently press the cell on the temporal conjunctiva (2 to 3 mm of the sclerocorneal 
limbus) for 5 seconds and remove the cell with a peeling technique (Illustration 1. Cytology per 
impression). Immediately fix with diethyl ether spray with one or two shots at 15 cm distance. The 
investigator will contact the Courier, within the first 24 hours, after the appointment designated by 
the sponsor for the shipment of the samples to histopathological analysis. You must complete the 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 30 of 65 
 
requisition form provided by the investigator and attach it to the mailing. The format will consist of 
three sheets (1 original and 2 copies) which will be assigned as follows: original sheet for the Courier, 
1 copy will be collected by the monitor and 1 copy will remain in the research center and will be 
filed in the corresponding folder to each research subject. 
 
Illustration 1. Cytology per impression 
 
The data of the histopathological report to be recorded in the CRF are: density of goblet cells and 
degree of squamous metaplasia according to the Nelson scale. (See Table 5) 
In the visits required to perform this procedure, it will be done prior to the use of ocular surface 
stains. 
Table 5. Nelson classification 
Grade 
Detail description of the epithelial 
cells 
Characteristics of goblet cells 
0 
Small and round cells; Large nuclei, 1: 
2 ratio with nuclear cytoplasm 
Abundant goblet cells (> 500 cells / mm2), globose and 
oval with an intense PAS-positive staining of the 
cytoplasm. 
1 
Slightly enlarged cells; smaller nuclei, 
1: 3 ratio with nuclear cytoplasm 
Marked decrease in the number of goblet cells (350 to 
500 cells / mm2) but still maintain their globose and oval 
shape and intense staining 
2 
Enlarged and polygonal cells; small 
nuclei, ratio 1: 4 to 1: 5 with nuclear 
cytoplasm 
Marked decrease in the number of goblet cells (100 to 
350 cells / mm2), less intense PAS - positive with poorly 
defined cell borders 
3 
Even larger and polygonal cells; small 
and pyknotic nuclei, 1: 6 ratio with 
nuclear cytoplasm 
Few goblet cells (<100 cells / mm2) 
Adapted from Nelson & Wright [24] [42]  
 
6.4.3.3 Eye comfort index 
It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to 
produce estimates on a linear scale of intervals (ratings: 0-100). Similar to the index for ocular 
surface diseases, the ocular comfort index (ICO) evaluates symptoms. The ICO contains 8 items (one 
positive and eight negative) that focus on the discomfort associated with alterations of the ocular 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 31 of 65 
 
surface. Each of these questions has two parts, which inquire separately the frequency and severity 
of the symptoms. [43] See annex 13.1 Eye comfort index. 
 
The evaluator will deliver the questionnaire to the subject and allow the subject to answer it calmly 
without any pressure and / or coercion, will only assist him if he has difficulty understanding any of 
the questions. 
6.4.3.4 Eye surface integrity: conjunctival hyperemia and chemosis 
This will be done by means of biomicroscopy using the slit lamp of the research center. A full 
assessment of the previous segment will be made, which will be recorded in the clinical file. The 
lighting techniques used will be at the discretion of the IP. 
The variables that will be registered in this protocol are: 
Conjunctival hyperemia.  
It is defined as the simplest reaction of the conjunctiva to a stimulus, a red appearance 
secondary to the vasodilation of the conjunctival vessels of variable intensity. He will 
graduate using the Efron scale. [44] See annex 13.2 Efron scale for conjunctival hyperemia 
- 
Chemosis.  
- 
It is defined as conjunctival edema, the result of an inflammatory reaction. It is qualified as 
present or absent. The evaluator will use a narrow beam of light at 60 ° and will measure if 
the conjunctiva separates from the sclera at ≥ 1/3 of the total palpebral opening or if it 
exceeds the gray line. [43] 
6.4.3.4.1 Stains 
• Staining with green lysine and fluorescein 
A drop of topical anesthetic will be instilled in the conjunctival cul-de-sac, then a second drop 
will be applied to the tip of the strip of green lysine and fluorescein and it will be allowed to 
slip towards the bottom of the sac. It is essential to quickly evaluate the staining, in sequence, 
first in the DO and then the OS, so that the observed patterns are equally bright. [19] See 
Annex 13.3 Oxford Scale 
The value obtained according to the Oxford scale will be registered in the CRF. 
6.4.3.5 Presence of adverse events 
The management of the EAs will be done according to what is described in section 9.3 Adverse 
events. The PI will register in the corresponding section of the CRF the EA that the subjects of the 
study will present, as well as referring it in their essential document. 
6.4.3.6 Intraocular pressure 
Tonometry is the objective measure of IOP, based primarily on the force required to flatten the 
cornea or the degree of corneal indentation produced by a fixed force. Goldman's tonometry is 
based on the Imbert-Fick principle. [38] The tonometry will be performed, after instillation of a drop 
of topical anesthetic (tetracaine 0.5%), with fluorescein and the use of the cobalt blue filter (after 
evaluation of the corneal surface staining). Three shots will be taken, which will be registered in the 
clinical file and the average will be registered in the CRF. 
6.4.3.7 posterior segment 
The evaluation of the posterior segment will be carried out under medication mydriasis (tropicamide 
0.8% / phenylephrine 5%), in the slit lamp with an aerial loupe (at the choice of the PI). An integral 
assessment of the fundus (including optic disk, posterior pole and periphery) will be performed in 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 32 of 65 
 
search of abnormalities that alter the study result. The result of the assessment will be recorded in 
the clinical file. In the CRF the assessment of the macula and optic nerve as normal, abnormal or 
abnormality that does not affect will be registered. 
6.4.3.8 Vital signs 
The vital signs to be evaluated (FC, FR and TAS) can be measured by an assistant duly indicated in 
the organization of the center and the delegation of responsibilities, the technique to be used for 
the FC and FR will be with the count of repetitions in one minute by Direct auscultation with 
stethoscope. 
The SBP should be measured with 5 minutes of previous rest, in the left arm. The instrument can be 
manual or automatic according to the IP. It is necessary that all measurements are equal in 
circumstances. 3 measurements will be made, with a minimum interval of 5 minutes between them. 
The IP will record the average in the note and the CRF. 
6.4.3.9 Ocular symptomatology 
The subject will be questioned directly about the presence in general (since the last visit) of the 
following symptoms: burning, foreign body sensation and pruritus. Respond about the severity and 
frequency of symptoms such as: 
Severity: Absent (0), very mild (1), mild (2), moderate (3) and severe (4) 
Frequency: At all times (4), almost at all times (3), 50% of the time (2), almost at no time (1), at any 
time (0). 
The number corresponding to each symptom will be registered in the CRF. 
Post-application symptomology: 
The subject will be requested, that in the subject's daily instrument, after registering the application 
of the product under investigation, mark YES or NO according to the presence of the following 
symptoms: burning, sensation of a foreign body, red eye and pruritus 
6.4.3.10 Breaking time of the tear film 
One of the first aspects of the tear film that changes when there is an alteration to the ocular 
surface, is its stability. In general, if the corneal or conjunctival surface is damaged, it is unlikely that 
a stable tear film can be maintained. 
The most common method to evaluate the stability of the tear film is the evaluation of TRL with 
fluorescein. Once the fluorescein is instilled, with the cobalt blue filter the patient is asked not to 
blink. The precorneal colored fluorescein layer will change to less fluorescent or non-fluorescent 
regions. The time that elapses from the last blink until the appearance of these regions is the TRL. It 
will be reported in seconds, in the clinical file and in the CRF. 
6.4.3.11  Pregnancy test 
It refers to the performance of a rapid pregnancy test in all women of childbearing age who wish to 
enter the study. By fertile age we understand women who have not had their menopause, defined 
as 12 months since the last menstrual period in women over 40 years of age; or those who 
underwent bilateral hysterectomy or oophorectomy. Women of childbearing age with 
contraceptive methods including bilateral tubal obstruction should be tested for pregnancy. This 
test will be carried out by the IP or the designated team person according to the instructions of the 
device delivered by the sponsor. When applicable, the completion, result and date must be 
registered in the CRF. If you do not apply, you must write down the reason 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 33 of 65 
 
6.4.3.12 Lab tests 
The PI will deliver to the subject the order of the studies of BH, QS and PFH, to be carried out in the 
clinical laboratory designated by the sponsor. The clinical laboratory will deliver to the IP the results 
for its assessment and registration. The normal parameters to be considered will be the ranges 
established by the laboratory, nevertheless the clinical criterion of the PI will prevail in the decision 
of normality or abnormality of the results. 
6.4.4  Measurement time 
The measurements of the variables of primary and secondary outcome will be made and evaluated 
for each visit, according to the following: 
Scrutiny Visit   
 
Some of these measurements should be complemented with those of the baseline visit and thus 
meet the eligibility criteria (see Schedule and study diagram), at the discretion of the PI. 
1. Signature of informed consent. 
2. General and ophthalmological clinical history. 
3. Laboratory sample taking. 
4. Pregnancy test. 
5. Review of selection criteria 
6. Visual ability 
7. Density of goblet cells (Cytology per impression) 
8. Intraocular pressure. 
9. Eye comfort index 
10. Evaluation of ocular signs and symptoms 
11. Integrity of ocular surface 
a. Epithelial defects (TF and TVL) 
b. TRL 
12. Subsequent segment evaluation. 
13. Vital signs 
 
Basal Visit / Day 0.   
Some of these measurements will be taken at the screening visit to complete the eligibility criteria 
(see Schedule and study diagram), at the discretion of the PI, they may be taken to complete the 
data of the baseline visit. 
1. Visual ability 
2. Density of goblet cells (Cytology per impression) 
3. Intraocular pressure. 
4. Eye comfort index 
5. Evaluation of ocular signs and symptoms 
6. Integrity of ocular surface 
a. Epithelial defects (TF and TVL) 
b. TRL 
7. Subsequent segment evaluation. 
8. Vital signs 
9. Evaluation of results of laboratory tests 
Visit 1 / Day 3  

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 34 of 65 
 
It can be done in a period ± 1 day in relation to day 3 of application. 
1. Visual ability 
2. Intraocular pressure. 
3. Evaluation of ocular signs and symptoms 
4. Integrity of ocular surface 
a. Epithelial defects (TF and TVL) 
b. TRL 
5. Vital signs 
6. Delivery of quality questionnaire. 
7. Evaluation of adverse events. 
 
Final Visit / Day 11.  
It can be done in a period ± 1 day in relation to the 11th day of the start of application. 
1. Visual ability 
2. Density of goblet cells (Cytology per impression) 
3. Intraocular pressure. 
4. Eye comfort index 
5. Evaluation of ocular signs and symptoms 
6. Integrity of ocular surface 
a. Epithelial defects (TF and TVL) 
b. TRL 
7. Subsequent segment evaluation. 
8. Vital signs 
9. Return and evaluation of quality questionnaire. 
10. Evaluation of adverse events 
 
Security call / Day 13. 
It can be done in a period ± 1 day in relation to the 13th day of the start of application. 
1. Ask about the presence of an adverse event. 
2. Evaluation of results of laboratory test 
 
 
 
 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 35 of 65 
 
 
 
6.5 
 Timeline and study diagram 
Procedures 
scrutiny 
Basal visit 
Visit 1 
Final visit 
Call Security 
  
Day 0 
Day 3 ± 1 
Day 11 ± 1 
Day 13 ± 1 
CI signature 
X 
 
 
 
 
clinic history 
X 
 
 
 
 
Ophthalmological clinical history 
X 
 
 
 
 
Laboratory sample taking 
X 
 
 
X 
 
Laboratory tests review 
 
X 
 
 
X 
Pregnancy test 
X 
 
 
X 
 
Eligibility criteria 
X 
Xa 
 
 
 
Assignment 
 
X 
 
 
 
Delivery of intervention 
 
X 
X 
 
 
Return of intervention 
 
 
X 
X 
 
Adherence evaluation 
 
 
X 
X 
 
Adverse events 
 
 
X 
X 
X 
Intraocular pressure 
X 
X1 
X 
X 
 
Visual ability 
X 
X1 
X 
X 
 
TRL 
X 
X1 
X 
X 
 
Epithelial defects (TF and TVL) 
X 
X1 
X 
X 
 
Eye signs and symptoms 
X 
X1 
X 
X 
 
Posterior Segment 
X 
X1 
 
X 
 
Vital signs 
X 
X1 
X 
X 
 
Ocular Comfort Index 
 
X 
 
X 
 
Goblet cell density (cytology by 
impression) 
 
X 
 
X 
 
Daily delivery of the subject 
 
X 
X 
 
 
Return 
/ 
Evaluation 
of 
the 
subject's Journal 
 
 
X 
X 
 
Delivery Quality Questionnaire 
 
X 
 
 
 
Return and Evaluation of the 
quality questionnaire 
 
 
 
X 
 
Continuity 
evaluation 
of 
the 
subject 
 
X 
X 
X 
 
a The eligibility criteria will be completed with the revision of the laboratory exams. 1 These measurements may be taken from the result of the 
screening visit, if it does not exceed the previous 7 days. It is the prerogative of the PI to decide whether to repeat the measurements at the 
baseline visit. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 36 of 65 
 
6.5.1 Procedures to be performed per visit 
6.5.1.1 Scrutiny visit 
▪ 
Signature of informed consent: refers to the signing of the written informed consent 
document. See 10.3 Consent 
▪ 
General and ophthalmological clinical history: refers to the technical, clinical and legal 
document in which the patient's health conditions, medical acts and other procedures 
performed on the patient are recorded chronologically. It includes the anamnesis and 
comprehensive ophthalmological exploration that allows to discern the patient's eligibility. 
If the patient is taken from the established consultation of the study center, he / she will be 
able to use the existing clinical history, only having to perform an update. 
▪ 
Taking laboratory samples: see 6.4.3.12 Laboratory tests. 
▪ 
Pregnancy test: see 6.4.3.11 Pregnancy test. 
▪ 
Eligibility criteria: refers to the review by the IP, where it states that the subject can be 
included in the study by meeting the inclusion criteria and not meeting the exclusion 
criteria. See 6.2 Eligibility criteria 
▪ 
Intraocular pressure: see 6.4.3.6 Intraocular pressure 
▪ 
Visual ability: see 6.4.3.1 Visual capacity 
▪ 
TRL: see 6.4.3.10 Rupture time of the tear film 
▪ 
Epithelial defects (TVL and TF): see 6.4.3.4.1 Stains 
▪ 
Eye signs and symptoms: see 6.4.3.4 Eye surface integrity: and 6.4.3.9 Ocular 
symptomatology 
▪ 
Posterior segment: see 6.4.3.7 Posterior segment 
▪ 
Vital signs: see 6.4.3.8 Vital signs 
6.5.1.2 Basal visit 
▪ 
Review of laboratory tests: refers to the review and analysis by the IP of the results of the 
BH, QS and PFH. See 6.4.3.12 Laboratory tests. 
▪ 
Eligibility criteria: with the laboratory results, the subject's profile will be finalized for 
inclusion or not. 
▪ 
Assignment: It refers to determining the intervention that the patient will follow during the 
study. It will be done according to section 7. Methods. Assignment of the intervention. This 
assignment will be made at the baseline visit (day 0) and will go along with the indication to 
start the treatment period the next day (day 1). 
▪ 
Delivery of intervention: Refers to the delivery of the product under investigation to the 
patient of the study, by the research center. It will be done according to sections 6.3.1 
Managed treatments and 6.3.4.1 Delivery and reception. 
▪ 
Evaluation of variables: The data of the evaluation of the variables listed below can be taken 
from the scrutiny visit, as long as it does not exceed 7 days prior to this visit. It is the IP's 
prerogative to decide whether to use the information from the screening visit or to repeat 
the evaluations on this visit. 
o Intraocular pressure 
o Visual capacity 
o TRL 
o Epithelial defects (TF and TVL) 
o Eye signs and symptoms 
o Subsequent segment 
o vital signs 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 37 of 65 
 
▪ 
Eye comfort index: see 6.4.3.3 Eye comfort index 
▪ 
Density of goblet cells (cytology per impression): see 6.4.3.2 Density of goblet cells (cytology 
per impression) 
▪ 
Delivery of the subject's diary: It refers to the delivery by the IP to the subject, the subject's 
daily instrument. 
▪ 
Delivery of quality questionnaire: It refers to the delivery by the IP to the subject, the quality 
questionnaire instrument. 
6.5.1.3 Visit 1 
▪ 
Intervention delivery: see 6.5.1.2 Baseline visit 
▪ 
Return of intervention: refers to the return of research products to the center by the 
research subject. 
▪ 
Evaluation of adherence: refers to the assessment made by the IP according to section 
6.3.2.1 Procedure to monitor adherence 
▪ 
Adverse events: see 6.4.3.5 Presence of adverse events 
▪ 
Intraocular pressure: see 6.4.3.6 Intraocular pressure 
▪ 
Visual ability: see 6.4.3.1 Visual capacity 
▪ 
TRL: see 6.4.3.10 Rupture time of the tear film 
▪ 
Epithelial defects (TF and TVL): see 6.4.3.4.1 Stains 
▪ 
Eye signs and symptoms: see 6.4.3.4 Eye surface integrity: and 6.4.3.9 Ocular 
symptomatology 
▪ 
Vital signs: see 6.4.3.8 Vital signs 
▪ 
Submission of the subject's diary: see 6.5.1.2 Baseline visit 
▪ 
Return / daily evaluation of the subject: refers to the delivery of the subject's diary to the IP 
by the subject. The IP will review the diary to assess its correct filler, evaluate the post-
application symptomatology and the registration of the applications. 
▪ 
Continuity assessment of the subject: refers to the determination by the PI and desire of 
the subject to continue with their participation in the study. 
6.5.1.4 Final visit 
▪ 
Laboratory sample taking: see 6.4.3.12 Laboratory tests 
▪ 
Pregnancy test: see 6.4.3.11 Pregnancy test 
▪ 
Return of intervention: see 6.5.1.3 Visit 1. 
▪ 
Adherence evaluation: see 6.5.1.3 Visit 1 
▪ 
Adverse events: see 6.4.3.5 Presence of adverse events 
▪ 
Intraocular pressure: see 6.4.3.6 Intraocular pressure 
▪ 
Visual ability: see 6.4.3.1 Visual capacity 
▪ 
TRL: see 6.4.3.10 Rupture time of the tear film 
▪ 
Epithelial defects (TF and TVL): see 6.4.3.4.1 Stains 
▪ 
Eye signs and symptoms: see 6.4.3.4 Eye surface integrity: and 6.4.3.9 Ocular 
symptomatology 
▪ 
Subsequent segment: see 6.4.3.7 Subsequent segment 
▪ 
Vital signs: see 6.4.3.8 Vital signs 
▪ 
Eye comfort index: see 6.4.3.3 Eye comfort index 
▪ 
Density of goblet cells (cytology per impression): see 6.4.3.2 Goblet cell density (Cytology 
per impression) 
▪ 
Return / daily evaluation of the subject: see 6.5.1.3 Visit 1. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 38 of 65 
 
▪ 
Return / evaluation of the quality questionnaire: refers to the delivery of the quality 
questionnaire to the IP by the subject.   
6.5.1.5 Security call 
▪ 
Adverse events: see 6.4.3.5 Presence of adverse events 
▪ 
Review of laboratory tests: see 6.5.1.2 Baseline visit 
6.5.2 Diagram of the study  
An enrollment time of 30 days is estimated for the total sample. 
In order to increase the safety of the participants with the use of the products under investigation, 
a partial analysis will be carried out following a modification to the Fibonacci method. This 
methodology will consist of including 33% of the total sample size (4 subjects per group, n = 8), 
which will complete all the visits and procedures described. Once this group of 8 subjects has 
finished their participation in the clinical study, a blinded analysis will be carried out. During the 
period in which this sub-analysis is carried out, the inclusion of new participants will be restricted. 
Inclusion will resume when the sponsor notifies the research center. 
In addition to safety, therapeutic adherence will be evaluated and problems related to procedures 
will be resolved, should they arise. 
 
Figure 1. Diagram of the study 
6.6 Sample size 
A total size of 24 subjects is estimated, divided into 2 intervention groups. (12 subjects per group) 
6.6.1 Calculation of the sample size 
Although there are no references on the calculation of the sample size in phase I studies, it was 
considered pertinent to perform it according to the presentation of adverse events referred by 
Christ T, in a randomized controlled trial of parallel groups, single blind, with randomization where 
10 days 
Waiting for 
laboratory 
results 
Corneregel® 
PRO-167 
Day 0 
Basal 
Visit 
Day 3 
Visit 1 
Day 11 
Final 
Visit 
Day 13 
Called 
security 
-1 a -7 
days 
Scrutiny 
Day 1 
Start 
application. 
Day 10  
End  
application. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 39 of 65 
 
it was evaluated the efficacy and tolerance of a 5% dexpanthenol ophthalmic gel versus a 5% 
panthenol ointment in 48 subjects with corneal erosion, keratoconjunctivitis by UV radiation or 
similar conditions. The intervention consisted in the application of 1 cm of the gel and the 
ointment during 4 and 3 days, respectively. [20] 
The percentage of good tolerance that was presented with the gel was 25%, so it is expected that 
no more than 10% of the subjects report a bad tolerance with the formulation proposed in this 
protocol. 
The sample size was calculated using the formula for proportions 
𝑛= 𝑝 (1 −𝑝) (
𝑍1−𝛼+ 𝑍1−𝛽
𝑝−𝑝0 − 𝛿)
2
 
With a statistical confidence of 95% corresponding to the type I error, equal to 1.96, with a power 
of 80%, corresponding to the type II error, equal 0.84. 
According to the previous calculation, the result is 19 subjects, which was increased by 20% for the 
probable losses. The total sample size required is 24 subjects. Therefore, each group will consist of 
12 subjects, who will provide an eye for analysis.  
6.7 Recruitment 
It is recommended that during the development of this research protocol, the principal investigator 
requests the approval of the Research Ethics Committee and the Research Committee, as well as 
the authorization to the relevant regulatory entity, to publish or disseminate in the mass media, the 
invitation to participate in the study to those people who meet the eligibility criteria. 
It is possible to discuss with other health professionals the opportunity for healthy subjects to be 
evaluated by an ophthalmologist at no cost, as well as cabinet exams that will allow the more 
accurate determination of their ocular clinical status by participating in a sponsored clinical research 
protocol. by Sophia Laboratories SA of C.V. 
 
7. Methods. Assignment of the intervention 
7.1 Generation of the allocation sequence 
The random numbers will be generated through the online tool: www.randomization.com 
Two strata corresponding to the intervention groups will be used, which will be balanced for a 
research center. The allocation will be 1: 1. 
7.2 Blinding mechanism 
Blinding will be performed by personnel assigned by the Clinical Operations Management of Sophia 
Laboratories S.A de C.V. Which will consist in the elimination of the primary label (commercial) in 
the case of Corneregel® and the placement of a label identical to the other interventions. Because 
the tube in which Corneregel® is packaged differs in the color and shape of the lid used by the PRO-

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 40 of 65 
 
167, a masking will be made in the secondary packaging which will be identical for the two 
interventions. 
7.3 Implementation 
The allocation sequence will be generated by personnel assigned by the Clinical Operations 
Management of Sophia Laboratories S.A de C.V. The research center will receive a set of envelopes 
which will contain the intervention number individually. The envelopes will be identical on the 
outside. Each of these envelopes will be shown to the participants for their election by the principal 
investigator or by a designated member of their team. 
7.4 Blinding (Masking) 
The blinding will correspond to the research subject and the principal investigator. In addition, the 
statistical analysis will be carried out in a blinded manner for the partial and final analysis. 
The masking will be done using boxes in the secondary packaging identical in the two groups. 
Blinding for the research subject and the researcher will be done by replacing the commercial labels 
in the case of the comparator in the tubes and the use of identical labels that contain the assignment 
number. 
7.4.1 Opening of blinding 
Blinding may be opened in the following cases: 
1. Presence of a serious adverse event. 
2. Safety alarm due to the use of the drugs under study. 
3. In case the sponsor determines it for any security reason or other reason that it considers 
pertinent 
8. Methods Collection, administration and data analysis 
8.1 Methods of data collection 
A clinical monitor will be assigned to each research center, which will be authorized to monitor, 
review, procure and ensure that the quality of the information obtained from the participants is 
reliable and trustworthy. Each monitor will schedule periodic visits to the research centers in order 
to review the source documents and corroborate the information captured in the case report format 
(CRF). All clinical monitors will be trained in relation to the information of the study protocol 
(objective, visits, procedures, range of accepted values, etc.). In the event that the data are not 
identical between the two registers, the clinical monitor will generate a discrepancy, which must be 
resolved by the research center in time that the sponsor deems reasonable to meet the objectives 
of the clinical study. The correction of the discrepancies will be made according to the Good 
Documentation Practices. 
The data registered in the CRF will be reviewed by personnel of Sophia Laboratories SA de CV, 
trained in the ophthalmological, clinical and pharmacological area, which will have the power to 
generate discrepancies in the event that the data do not comply with the stipulations of the research 
protocol or put participants at risk. 
Once all discrepancies generated by the team of clinical monitors and clinical staff have been 
resolved, the data will be downloaded into an electronic database (Excel Sheet) by personnel 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 41 of 65 
 
designated by the sponsor. A new review of the data will be carried out to corroborate the fidelity 
of the same and new discrepancies may be generated in case it was considered. 
The database generated will be safeguarded by the sponsor and will only have personal access 
designated by the same. 
8.1.1 Strategies to complete the follow-up 
• You will be clearly informed of the importance of the study and the benefits that the 
population will obtain from the results of the study. 
• Transportation assistance will be provided in order for the participant to attend their visits. 
• Calls, messages or a printed calendar will be made in order to remind the participant of 
their appointments and the activities that will be carried out, in addition to the estimated 
duration of the same. 
• In case the participant does not attend his appointment, the research center must make 
a call to know the reason and try to arrange a new appointment within the established 
window period or an unscheduled appointment. 
• In case it is not possible to make an appointment, it will be asked about the presence of 
adverse events and the reason for leaving the study, as minimum data. 
8.2 Data management 
The subject's medical record (including clinical notes, test results, etc.), the subject's diary, and the 
ICO questionnaire are considered source data. 
The PI or the designated person of your team will fill out the Case Report Format (CRF) with all other 
documents provided by the sponsor (for example, documents related to the handling of the 
treatment). 
A CRF was designed to record the data that are required in the protocol and that the researcher 
collects in each of the visits. 
In the case of self-assessment questionnaires, it is not permissible for the principal investigator or 
person responsible for filling in to modify what was written by the subject of the study. 
The data capture in the investigator's site will be done by the investigator or the designated person 
of his team after performing the Medical File. The researcher or a designated person of your team 
will be trained in filling the CRF. 
All corrections to the CRF data should be made by the investigator or the designated person of your 
team in accordance with the instructions provided. 
To ensure the confidentiality and security of the data, user names and access codes will be used to 
restrict access to the system only to authorized personnel. 
The monitor must ensure that all the data has been filled in the CRF. After comparing the data 
against the source documents, the monitor will ask the researcher to make the necessary correction 
/ clarification, so that they are answered and closed as quickly as possible. 
The Scientific Committee of Laboratories Sophia S.A. of C.V. will give the latest medical-scientific 
review, and will set the pattern to freeze the database. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 42 of 65 
 
8.3 Statistical methodology 
8.3.1 Analysis of primary and secondary outcome variables 
The statistical analysis will be carried out by personnel of Sophia Laboratories. The statistical 
program SPSS version 19 (IBM Corporation, Armonk, NY, USA) will be used. 
The designated personnel will be blinded to the intervention groups. The coding will be done using 
consecutive numbers for each intervention group. 
The data will be collected and sorted in an excel sheet. Later they will be exported to the platform 
of the SPSS program. The variables will be categorized according to their nature. 
The result of the continuous quantitative variables will be presented in measures of central 
tendency: mean, standard deviation and ranges. See Table 4. Scales to be used 
The normal distribution of the results will be obtained by the Kolmogorov-Smirnov test. 
The statistical analysis of the continuous quantitative variables to find significant differences (p) will 
be the following: 
• Intra-group analysis: Wilcoxon rank test. 
• Inter-group analysis: Mann-Whitney U test. 
The level of difference to consider significance will be an alpha of 0.05 or less. 
The result of nominal and ordinal qualitative variables will be presented in frequencies, proportions 
and percentages. 
The statistical analysis to identify significant differences of the qualitative variables will be done 
creating 2x2 contingency tables and it will be carried out in the following way: 
• Intra-group difference: McNemar or Pearson test. 
• Difference between groups: test χ2 (Chi-square) of Pearson. 
The level of difference to consider significance will be an alpha of 0.05 or less. 
For the reporting of adverse events all eyes of those participants who were randomly assigned to 
an intervention group after the baseline visit will be considered. The results will be expressed in 
number of cases (eyes). 
The final report of the results will be shown in tables or graphs, as appropriate. 
It will be considered that the investigational drug is safe and tolerable when there are no clinical 
and statistical differences in all the variables of primary outcome, with respect to its comparator. 
Those subjects who comply with an adherence greater than 60% will be included in the statistical 
analysis to meet the objective of the study. It was considered that from the minimum dose necessary 
to obtain a pharmacological effect (reepithelizer / 1 cm per day) and the presence of adverse events 
(exposure) is sufficient to meet the overall design objective, according to the pharmacological 
characteristics of the product in investigation. 
8.3.2 Additional analyzes 
A partial analysis will be carried out with the objective of evaluating safety and adherence once 4 
subjects per group (33% of the sample size) have completed all the visits and study procedures. Non-

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 43 of 65 
 
parametric statistics will be used and the same mechanisms described will be used for the total 
analysis of the data. 
8.3.3 Population analysis and management of missing data 
An analysis will be carried out by intent to treat where the data of the participants that have fulfilled 
two visits will be included (Basal Visit and visit 1).  
 
 
9. Methods Monitoring 
9.1 Data monitoring 
Monitoring visits by a site monitor of Sophia Laboratories S.A. of C.V. are intended to confirm that 
studies sponsored by Sophia Laboratories S.A. of C.V. they are conducted in accordance with the 
ethical principles that have their origin in the Declaration of Helsinki and that are consistent with 
Good Clinical Practices and with the applicable regulatory requirements (verifying a continuous 
compliance with the protocol, amendment or amendments, reviewing accounting records of the 
product under investigation, verifying that the personnel of the site and the facilities remain 
adequate to carry out the study). 
The researcher must ensure that they have sufficient time, space and qualified personnel for the 
monitoring visits. 
In order to carry out the monitoring review, it is mandatory to provide direct access to all source 
data and those related to the study site. The monitor will conduct a review of the CRF and a 
Verification of Source Documents (VDF). By VDF means the verification of the records in the CRF 
through its comparison with the source data that the researcher will make available for this purpose. 
Regarding the CRF, the monitor will mark in each visit the screens completed and approved in case 
of use of electronic platform. 
In accordance with the applicable regulations, Good Clinical Practices, and the procedures of Sophia 
Laboratories A.S. of V.C. The monitors of Sophia Laboratories A.S. of V.C. they will contact the site 
before the start of the study to review the protocol, the regulatory and ethical requirements of 
Sophia Laboratories, S.A. with the staff of the site. of C.V. When reviewing the procedures for data 
collection, the conversation will also include the identification, agreement and documentation of 
the individual data for which the records in the CRF serve as source documents. 
Sophia Laboratories A.S. of V.C. will monitor the study to verify, among other things, that: 
• The data is authentic, correct and complete. 
• The safety and rights of the subjects are being protected. 
• The study is being carried out in accordance with the currently approved protocol, any other study 
agreement, Good Clinical Practices and all applicable regulatory requirements. 
The investigator and the head of the medical institution (when applicable) agree to allow the 
monitor to have direct access to all relevant documents. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 44 of 65 
 
Study monitoring visits will be conducted at regular intervals, depending on the recruitment rate, 
under the arrangements between the investigator and the sponsor. All information related to these 
visits will be handled as strictly confidential. 
Upon completion or early termination of the study, the monitor will carry out site closure activities 
with the investigator or site staff, as appropriate, in accordance with applicable regulations, Good 
Clinical Practices, and Sophia Laboratory procedures. , SA of C.V. 
 
After the study is closed, the researcher must keep all study records on the site in a safe place. 
Records should be maintained to allow easy and timely recovery, when necessary (for example, in 
an audit or inspection). Sophia Laboratories A.S. of V.C. will inform the investigator / institution the 
period of time they will have to retain these records, in order to comply with all applicable regulatory 
requirements. However, the investigator / institution must seek the written approval of the sponsor 
before proceeding to the elimination of these records. The minimum retention time will satisfy the 
most stringent standard applicable to that site for the study, in accordance with the provisions of 
the PCBs, any institutional requirements or the applicable laws or regulations, or the standards / 
procedures of Sophia Laboratories A.S. of V.C. The researcher / institution must notify Sophia 
Laboratories A.S. of V.C. Of any change in file arrangements including, without limitation, the 
following: file in an off-site facility, transfer of ownership of records in the event the investigator 
leaves the site. 
9.2 Preliminary analysis and early termination of the study 
The partial analysis described in section 8.3.2 Additional analyzes will allow the sponsor to make a 
decision about the early termination of the study in the event that the safety of the participants is 
compromised. 
The early termination of the study will be considered in the following cases: 
1. Presence of serious adverse events in more than 5% of the participants in each 
intervention group. 
2. The competent authority (COFEPRIS) considers it for security alerts. 
3. The Sponsor determined it for his convenience or eventualities such as: economic 
support, manufacturing errors, etc. 
4. Lack of recruitment as expected. 
 In case the decision is the early termination of the clinical study, all the research centers will be 
informed within the first 24 hours by the available communication channels. Likewise, the 
corresponding authority in each country will be informed (if applicable) and the Ethics Committees 
involved. 
Each research center has the obligation to inform the subjects that participate in the clinical study 
in a period no longer than 24 hours, after receiving the information from the sponsor. You must 
inform all the subjects involved in any phase of the study. 
The result of the preliminary evaluation will be in charge of the Clinical Operations Management 
and the Medical Management of Sophia Laboratories A.S. of V.C., which will have the faculty to 
determine the destiny of the present protocol, according to judge convenient. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 45 of 65 
 
 
9.3 Adverse events 
9.3.1 Investigator's responsibilities 
Perform the verification of adverse events through questioning, relevant physical examination, 
assessment of evolution, as well as adequate medical and pharmacological management, resolution 
or outcome and final discharge following the definitions determined in national and international 
regulations. [45] [46] [47]  
In case of adverse events or any event that puts the health and well-being of the patients at risk, 
appropriate medical attention will be provided, either at the research site or will be referred to the 
Hospital Center with greater resolving power with which the researcher and / or researcher site 
have medical care agreement. The researcher will notify the clinical monitor of the sponsor, 
according to the times established in the national and international regulations. In the case of 
serious adverse events, notify the sponsor and record the corresponding information in the case 
report form and in turn inform the Research Ethics Committee to the Research Committee. 
The attention of the adverse events will be made according to the diagram of attention of the event 
(see Figure 3. Attention of the adverse event) 
In the final report to be drafted by the Scientific Committee of the Department of Clinical Operations 
of Sophia Laboratories A.S. of V.C., will include the report of adverse events in compliance with 
current national and international regulations. [46] [47] 
9.3.1.1 Record of adverse events in the Case Report Form 
The registry of adverse events considers the information concerning the identification data of the 
participating patient as code, age, sex, left eye, right eye. 
Information about the type of adverse event, adverse reaction or suspected adverse reaction to the 
product under investigation or to the study medication, as appropriate. The date on which the 
adverse event occurs is reported, as well as in which the Investigator is aware of it, date of resolution 
or outcome, as applicable. The clinical diagnosis is indicated. Include in concomitant medications 
the therapy used for the pharmacological management of the adverse event, suspected adverse 
reaction, adverse reaction. Record the outcome or resolution of the event: patient recovered 
without sequelae, with sequelae, not recovered. Patient who presented death due to adverse 
reaction / adverse event, patient who presented death and it is judged that the drug could have 
contributed, patient who presented death and this is not related to the investigational product or 
drug, or indicate that it was not He knows what the consequence of the event is. 
Consign information about the product or drug under investigation or the drug associated with the 
adverse event, adverse reaction or suspected adverse reaction. As applicable, information 
concerning generic denomination, distinctive denomination or product code in research and / or 
investigational medication should be recorded, as appropriate according to the methodological 
design of the study, this is relevant in the case of blinded studies or those where they use placebo 
as comparators, since there are circumstances that justify opening the cecum to determine if the 
adverse event, the adverse reaction or suspected adverse reaction may be attributable to the active 
agent, the combination of active agents, or the substance (s). s) pharmacologically inert (s), such as 
vehicles or additives, as appropriate the phase of clinical research in which the development of the 
drug is located. It will also be necessary to record the data concerning the batch number, 
manufacturer laboratory, expiration date, dosage, route of administration, start and end dates of 
administration and / or consumption, reason for the prescription; according to whether it is a 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 46 of 65 
 
product or investigational medicine (protocol in which the patient currently participates) or is a 
medicine that the subject under investigation consumes for the treatment of basic concomitant 
diseases or used for the management of any sign or transient symptom that does not correspond 
to the Natural History of the pathology that motivated its entry into the research protocol.  
Record the withdrawal or maintenance of the medication, investigational product or investigational 
medication, as appropriate. Indicate if the adverse event disappears when the investigational 
product or investigational medication or suspicious medication is removed (to provoke the event). 
Also indicate if a dose adjustment is made, if the event changes in terms of intensity or seriousness, 
persistence of the reaction. It is important to indicate that in those patients who are exposed again 
to the investigational product, investigational medication or medication, which had previously been 
suspended, if the adverse reaction or adverse event reappears. 
Regarding concomitant pharmacotherapy. Indicate the generic name, the dose, the route of 
administration, start and end dates of its use, as well as the reason for the prescription regardless if 
it is consistent with the information to prescribe or technical data sheet or is used outside the 
regulations or of what the local, national or international regulatory entity has authorized. 
Concerning the relevant clinical antecedents. The analysis of the adverse event, adverse reaction or 
suspicion of adverse reaction considers the information previously reported, notwithstanding the 
clinical context in which said harmful phenomenon occurs in the participants of the clinical research 
protocol, it is of special interest, so that the information about previous ailments, hypersensitivity 
or allergy phenomena, previous surgical procedures, laboratory analysis or cabinet exams that have 
been practiced on the participant, etc., that the researcher deems convenient to mention may do 
so. If you have enough space in the case report format, you can complement the information of 
your clinical note in the clinical file. 
9.3.1.2 Follow up of adverse events 
The IP will provide the attention and guidance of the EA that the participant presents until the 
outcome of the same, according to what is referred to in the following section. 
9.3.1.3 Procedures for a serious adverse event 
The process of attention of the adverse event considers the following stages: 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 47 of 65 
 
 
Figure 3. Attention to the adverse event 
A. During the development and conduct of the present clinical research, undesirable damaging 
events or adverse reactions, of medical implication, which do not necessarily have a causal 
relationship with the investigational product or investigational medication, may occur in the 
participant patient. These harmful phenomena can occur during the use of investigational 
drugs, unintentionally, at doses authorized for use in humans; by a local, national or 
international regulatory entity, whether for prophylaxis, diagnosis, treatment or for the 
modification of some physiological process. However, it can be suspected that the 
investigational product or the investigational drug or the placebo cause some unwanted 
clinical manifestation. Adverse events, adverse reactions or suspected adverse reactions to 
one or several medications can occur during the systematic evaluation of the participants 
(on the days when the clinical review is scheduled, according to the schedule of activities) 
or suddenly, as such way that, 
B. The investigator must be the first person to whom the patient reports that they have 
developed or presented a harmful clinical phenomenon during their participation in this 
research protocol. 
C. According to your clinical judgment; on the basis of the pertinent physical examination, 
interrogation, etc., as well as the analysis of the information available in the medical 
literature and that referred to in the investigator's manual, information to prescribe or 
technical data sheet of the comparator drug, the principal investigator determines the 
relevant attention of the event / harmful reaction; either 
D. In the research site or in the hospital with the greatest resolving power (1st, 2nd or 3rd level 
of medical attention). In such a way that, in case the patient is sent by the Investigator to a 
hospital, he / she attends by means of a reference system, it can be with an identification 
card that the patient belongs to the present investigation and there is an official number or 
folio, which pertains to the emergency care agreement with the health institution with the 
greatest resolving power, or a medical reference note issued by the principal investigator, 
so that appropriate care is given to the participating patient. It should be noted that the 
Study Sponsor, Sophia Laboratories, S.A. C.V., will pay the expenses for the medical care of 
the participating patient, only if the adverse event, adverse reaction or suspected adverse 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 48 of 65 
 
reaction to medication is associated or found in relation to the investigational product or 
investigational medication. 
E. Taking the clinical information collected, either during the care provided at the research site 
or provided by the treating physician (s) in the hospital, the principal investigator records 
the adverse event, suspected reaction adverse or adverse reaction to medication in your 
clinical note of the clinical record, indicating the seriousness, intensity (mild, moderate or 
severe), relationship with the investigational product or medication, as well as: 
F. The migration of the relevant data to the case report format and to its respective adverse 
event section; noting the pertinent information, already referred to in section 9.3.1.1., this 
in virtue of the fact that in cases of serious adverse events, which must be notified in less 
than 24 hours after the moment in which the principal investigator has knowledge of the 
same, the clinical monitor of the study is informed, so that in turn he / she informs the 
Scientific Committee and the Pharmacovigilance Department of the sponsor and later he / 
she informs the Research Ethics Committee. Regarding non-serious adverse events, these 
will be recorded and adequately addressed and the corresponding regulatory entity will be 
informed about the safety profile of the investigational product or investigational 
medication in the final report of the clinical trial. 
The record of the outcome of the adverse event, suspicion of adverse reaction or adverse reaction 
to medication depends substantially on the follow-up that the principal investigator makes to the 
participant, since most of the harmful phenomena are expected, consult section of the safety profile 
in number 5.3 and in the researcher's manual, they are ophthalmic in nature, however there may 
be systemic alterations. Therefore, in the opinion of the researcher, the withdrawal or permanence 
of the participant will be considered, according to the provisions of section 6.2.2 Exclusion criteria 
of the present research protocol. 
9.3.1.4 Causality evaluation 
The assessment of the causality, the methodology used to estimate the probability of attributing to 
a drug, investigational drug or investigational product the adverse reaction, the suspicion of the 
same or the observed adverse event, considers probabilistic categories, according to the evidence 
available and the quality of information, based on national pharmacovigilance regulations. [47] As 
a tool to facilitate the probabilistic categorization of causality, the principal investigator can use the 
algorithm of Karch and Lasagna modified by Naranjo referred by Aramendi I, 2011 in which different 
items are qualified which allow assigning a value to the relationship cause-effect between the 
administration of the drug and the adverse reaction. [48] See Table 6. Algorithm of Karch and 
Lasagna modified by Naranjo 
 
 
 
 
 
 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 49 of 65 
 
Algorithm of Karch and Lasagna modified by Naranjo 
No. 
Reagent 
Score 
yes 
No 
1. 
There are previous conclusive reports about the adverse drug reaction, adverse 
event or suspected adverse drug reaction 
+1 
0 
2. 
The adverse event appeared when the suspected drug was administered 
+2 
-1 
3. 
Adverse reaction to medication, adverse event or suspected adverse drug 
reaction improved upon discontinuation or administration of a specific 
antagonist 
+1 
0 
4. 
Adverse reaction to medication / adverse event / suspected adverse drug 
reaction reappeared when administering the drug / investigational product / 
investigational medication 
+2 
-1 
5. 
There are alternative causes that may cause this reaction 
-1 
+2 
6. 
Adverse reaction / adverse event / suspected adverse drug reaction occurred 
after placebo administration 
-1 
+1 
7. 
The drug was determined in blood or other liquids in toxic concentrations 
+1 
0 
8. 
The intensity of the adverse reaction / adverse event / suspected adverse drug 
reaction was higher with higher doses or lower with lower doses 
+1 
0 
9. 
The patient has had similar reactions with the drug / product under 
investigation or investigational medication, in the past 
+1 
0 
10. 
Adverse reaction / adverse event / suspected adverse reaction to medication 
was confirmed with some objective evidence 
+1 
0 
                                                                                                                               Totalscore 
summation 
Probabilistic category based on the score obtained 
I 
The causal relationship is checked 
≥,9  
II 
It is likely that ADR is due to the drug or product under investigation 
5 a 8 
III 
It is possible that the RAM is due to the drug or product under investigation 
1 a 4 
IV 
The causal relationship is doubtful 
0 
The reagents considered by the algorithm of Karch and Lasagna modified by Naranjo where each one receives a defined score are 
shown and the final summation allows estimating the probabilistic category of the cause-effect relationship between the 
administration of the drug / product in research / investigational medicine and the adverse reaction, adverse event or suspected 
adverse reaction. Consider that if the information is not available, a score equal to zero is recorded. 
Table 6. Algorithm of Karch and Lasagna modified by Naranjo 
 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 50 of 65 
 
In such a way that the degree of certainty to establish the investigational product or investigational 
medication (as appropriate) as the causal agent of the harmful phenomenon that befalls the 
participating patient, can be directly indicated by the principal investigator based on his or her 
clinical experience or well through the voluntary application of the tool mentioned previously. 
However, it is important that the researcher take into account the following arguments in favor of 
the causal relationship: 
 
a) Force of association that refers to the number of cases in relation to those exposed. 
b) The consistency of the data, ie the presence of a common characteristic or pattern. 
c) The exposure-effect pattern: which determines the relationship with the site of onset, 
 
time, dose and reversibility after suppression. 
d) The biological plausibility: which refers to the possible pharmacological or 
 
physiopathological mechanisms involved in the development or presentation of the adverse 
event. 
e) Experimental findings: for example the appearance of anomalous metabolites or high 
 
levels of drug or the product of its biotransformation. 
f) Analogy: experience acquired with other related drugs, adverse reactions frequently 
 
produced by the same family of pharmacological agents. 
g) Nature and characteristics of the data: objectivity, accuracy and validity of the relevant 
 
documentation. [49] 
9.3.2 Responsibilities of the sponsor 
The sponsor will be responsible, and will cover the expenses derived from medical attention to 
adverse events related to the product under investigation. 
9.4 Audit 
To guarantee compliance with the PCBs and with all applicable regulatory requirements, Sophia 
Laboratories A.S. of V.C. could carry out a quality assurance audit. Regulatory agencies could also 
carry out a regulatory inspection of this study 
9.4.1 Pre-study audit 
The research centers included in the study will be subject to a feasibility visit prior to the selection 
of the center, where it will be verified that they meet the minimum requirements indicated by the 
sponsor. 
9.4.2 Audit / Inspection during the conduction of the study 
They may take place at any time before, during or after the conclusion of the study. If an audit or 
inspection is performed, the investigator and the institution should agree to allow the auditor / 
inspector direct access to all relevant documents, and will allocate their time and that of their staff 
to the auditor / inspector to discuss the findings and any relevant problems. 
10. Ethical considerations 
10.1 Approval of the committees 
 
The present study will be conducted according to the standards of the Declaration of Helsinki, World 
Medical Association 2013. Nuremberg Code; Nuremberg Trial by the International Court of 
Nuremberg, 1947. Belmont Report, National Commission for the Protection of Subjects of 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 51 of 65 
 
Biomedical Research and Conduct, 1979. Will be conducted in accordance with the scientific and 
technical requirements necessary for the registration of medicines for use of the International 
Conference on Harmonization (The International Council for Harmonization, ICH) Guide to Good 
Clinical Practices. International Ethical Guidelines for Biomedical Research in Human Beings of the 
Council for International Organizations of Medical Sciences (Council for International Organizations 
of Medical Sciences, CIOMS, 2002). International Ethical Guidelines for epidemiological studies of 
the Council for International Organizations of Medical Sciences (Council for International 
Organizations of Medical Sciences, CIOMS, 2008). 
The Research Ethics Committee and the Research Committee will evaluate the protocol before 
conducting the study and will issue their approval or possible modifications for its realization, these 
Committees should be notified of any significant changes to the protocol. In addition to the above, 
the current regulations issued by the Ministry of Health will also be complied with. General Health 
Law, NOM 012 Official Mexican Standard NOM-012-SSA3-2012, Which establishes the criteria for 
the execution of research projects for human health. The study is considered as an investigation 
with a risk greater than the minimum according to the Regulation of the General Health Law on 
Health Research, Title Two, Chapter I, Article 17, Category III, published in the Official Gazette on 6 
January 1987 
The principal investigators or study coordinators or personnel authorized by the sponsor will be 
evaluated by the Research Ethics Committees, Research Committees, and when applying to the 
Biosafety Committee the essential documentation of the research project: research protocol, letter 
of informed consent, researcher's manual, subject's diary, as well as those requested, in addition, 
according to local, national or international requirements applicable by regulatory entities. 
The study will not start in the research site if you do not have the confidentiality agreements and 
economic proposal of each of the principal investigators, duly signed and without having previously 
obtained the favorable opinion and / or the approval of the Committees of Ethics in Research, 
Research Committees, and when applicable by the Biosecurity Committee, corresponding. 
The study will not begin without having met the relevant local, national or international regulatory 
requirements and without having the corresponding health authorization. 
10.2 Amendments to the protocol 
The amendment procedure will be relevant when there is a need to make any change to a document 
that is part of the research project or protocol, derived from variations in the methodological 
structure, substitution of the principal investigator or when identifying risks in the research subjects 
. The documents susceptible of amendment will be: protocol, letter of informed consent, 
researcher's manual, documents for the patient, scales of measurement and schedule of activities. 
Any amendment must be approved by the sponsor and / or the principal investigator, the amended 
document (s), once reviewed and approved by the Research Ethics Committee and the Research 
Committee or when applicable, by the Committee of Inquiry. Biosafety, (entities that issued the 
initial favorable opinion for the conduct of the investigation) will be sent (s) for authorization by the 
relevant regulatory entity. 
Amendments that substantially modify the protocol or confer an additional or different risk to the 
research subjects must be approved by the Committee. It is the investigator's responsibility to take 
action in situations that require immediate action to avoid unnecessary harm to the study 
participants. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 52 of 65 
 
The principal investigator has the responsibility to inform the Research Ethics Committee of any 
amendment to the protocol that could eventually affect the rights, safety or welfare of the research 
participants. Likewise, he must know any situation or new knowledge that shows a greater risk for 
the participants, the termination or premature suspension of the study, the reasons and the results 
obtained up to that moment. You must also inform about the conclusion of the study, when 
completing the research protocol. 
The list of amendments, and in the necessary cases, the relation of the issuance of errata, will be 
referred to in the final report of the investigation. 
10.3 Informed consent 
10.3.1 Obtaining 
Informed consent must be obtained before the subject undergoes any procedure indicated in the 
protocol. 
The written consent documents will incorporate the elements of informed consent described in the 
Declaration of Helsinki and the ICH Guide to Good Clinical Practices and will be in compliance with 
all applicable laws and regulations. 
The PI will provide the potential participant with all the information regarding the characteristics of 
the study, its potential benefits, risks, objectives and procedures thereof. 
This information will be with a language understandable to the subject, it will be explained to the 
subject that has the right to interrupt their participation in the study at any stage, without affecting 
the relationship with the researcher and / or their future assistance. The informed consent will be 
put to the consideration of the possible participant; This must have enough time to analyze each 
and every one of the aspects mentioned above and if there is any doubt this will be clarified by the 
person in charge of obtaining the informed consent. 
Once the participant agrees to participate in the study, he / she must sign and date the informed 
consent letter in the presence of two witnesses who have or are not related to the subject of study, 
who will participate during the informed consent process and will sign endorse that the process was 
carried out prior to any study procedure, that the study information was clearly explained and 
doubts were clarified if they existed. 
If a subject is illiterate, the acceptance will be with their fingerprint, and in the event that the subject 
is not able to grant an informed written consent, a representative of the "legally authorized" subject 
can provide such consent. The subject in accordance with applicable laws and regulations. 
The IP must also sign and date this consent. 
The informed consent must be signed in duplicate by all involved, and two witnesses. One copy will 
be filed in the file of the subject and the other will be delivered to the participant. The PI must 
document the obtaining procedure, the date and time and the questions asked by the subject in 
which he signed the informed consent in the subject's medical history. 
 
 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 53 of 65 
 
10.3.2 Special considerations 
The auxiliary studies that will be carried out during the conduction of the study (laboratory tests) do 
not pose an additional risk that should be considered apart from the procedures listed in the 
informed consent. 
10.3.3 Modification to informed consent 
Any change to "informed consent" constitutes an amendment to this document and must be 
submitted for approval to the Research Ethics Committees, and if applicable before the Competent 
Authorities. 
The amendment will include a copy of the new version in the language or languages of the country. 
Such amendments may be implemented only after obtaining the written approval of the Research 
Ethics Committee and the Regulatory Entity (as applicable), with the exception of an amendment 
that is required to eliminate an immediate danger to the subjects of the study. 
For each subject affected by the amendment their consent must be obtained again. This new version 
should be obtained following the same procedure that was performed for the inclusion of the 
subject, at the beginning of the protocol. Therefore, the IP must document the process of obtaining 
the most current version of the consent in the subject's medical history. 
10.4 Confidentiality 
All documents and information provided to the researcher by the sponsor are strictly confidential. 
The researcher expressly agrees that the data on their professional and clinical experience, provided 
to the sponsor on paper and stored in electronic format, are only for use related to their activities 
with the sponsor of clinical studies, in accordance with Good Clinical Practices. The researcher 
accepts that he / she and the members of his team will use the information only within the 
framework of this study, to carry out the protocol. This agreement is mandatory as long as the 
confidential information has not been disclosed to the public by the sponsor. The protocol of the 
clinical study provided to the researcher may be used by him and by his colleagues to obtain the 
informed consent of the subjects for the study. The clinical trial protocol, like any information taken 
from it, should not be disclosed to other parties without the sponsor's written authorization. 
The researcher will not reveal any information without the prior written consent of Sophia 
Laboratories A.S. of V.C., except to the representatives of the Competent Authorities, and only by 
request of the same. In the latter case, the researcher undertakes to inform Sophia Laboratories 
A.S. of V.C. before revealing the information to these authorities. 
The researcher will fill out and maintain a record of the subjects' selection, as well as the 
identification and enrollment list of each of the subjects participating in the study. The researcher 
agrees to give on-site access to the auditor and / or the representatives of the Competent 
Authorities. The information will be treated in compliance with professional secrecy. 
10.5 Deviations 
A deviation is any alteration in the procedures and activities described in the research protocol 
approved by the committees and regulatory authorities. They may be the product of modifications 
or omissions, and may compromise the safety of the participants or the quality of the data 
generated. 
Major deviation / violation: is one that impacts one or more of the following aspects: 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 54 of 65 
 
- 
Subject security 
- 
Alteration of the risk-benefit balance 
- 
Commit the integrity of the study data 
- 
Affects the voluntariness of the subject in the participation of the study. 
The list of examples cited below serves the purpose of guidance, but does not cover all possible 
cases, so it is not limiting: 
I. 
In relation to informed consent: 1) that informed consent has been taken by an 
unauthorized person to do so, 2) that the subject under investigation signs a version of 
informed consent not approved by the committees and regulatory entity, 3) that perform a 
study procedure prior to signing informed consent. 
II. 
Regarding the inclusion / exclusion criteria: 1) enroll subjects who do not meet all the 
inclusion criteria and / or meet any exclusion criteria, 2) enroll defined subjects as part of 
the so-called vulnerable population: children, pregnant women, prisoners, without prior 
approval for such group; 3) Enroll patients before the start or after the end of the study. 
III. 
In relation to the medication of the study: error in the delivery or dosage of the same. 
IV. 
In relation to concomitant medication: use of prohibited medication. 
V. 
V. In relation to the study procedures: that those that, in the opinion of the principal 
investigator, compromise the safety of the research subject are not carried out.  
VI. 
In relation to the reporting of serious adverse events: those that are reported outside the 
time stipulated by the committees. 
Minor desviation: is that which does not impact on the safety of the subject, does not alter the risk-
benefit balance, does not compromise the integrity of the study data or does not affect the subject's 
willingness to participate in the study. 
The list of examples cited below serves the purpose of guidance, but does not cover all possible 
cases, so it is not limiting: 
I. 
Oblivion in the taking of the study medication. 
II. 
Lack of return of study medication by the subject. 
III. 
Visits of the research subject carried out outside the window. 
 
10.5.1 Management of deviations 
All deviations must be reported by the IP to the sponsor and the corresponding committees. 
At your discretion, and depending on the severity of the deviation, the sponsor and the 
corresponding committees may: 
 
- Request more information. 
 
- Citing the principal investigator and / or the members of his team. 
 
- Temporarily suspend the researcher for present and / or future investigations until the 
 
situation is resolved and / or considers the explanations given by the person (s) responsible 
 
for the deviation satisfactory. 
 
 
 
 
- Carry out an audit for cause. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 55 of 65 
 
 
10.6 Declaration of interests 
The PI undertakes to make a declaration of financial interests, as well as a conflict of interests prior 
to the start of the study. 
10.7 Access to information 
The final database of the study will be owned by Sophia Laboratories A.S. of V.C. and your access 
will be restricted. The IP will not have access to it, unless it has prior written authorization from the 
sponsor. 
10.8 Auxiliary care and after the end of the study 
Once the study is completed and the adverse events are closed according to section 9.3 Adverse 
Events, the sponsor will not extend care on the research subject. 
10.9 Biosecurity aspects 
WITHOUT BIOSECURITY IMPLICATIONS 
The present protocol, with title: "Phase I clinical study, to evaluate the safety and tolerability of the 
ophthalmic gel PRO-167 versus Corneregel®, on the ocular surface of ophthalmological and clinically 
healthy subjects", and number: SOPH167-0816 / I DOES NOT HAVE BIOSECURITY IMPLICATIONS, 
since infectious-contagious biological material will NOT be used; pathogenic strains of bacteria or 
parasites; viruses of any kind; radioactive material of any kind; genetically modified animals and / 
or cells and / or plants; toxic, dangerous or explosive substances; any other material that endangers 
the health or physical integrity of the personnel of the research center or the subjects of 
investigation or affects the environment. It is also stated that cell, tissue or organ transplant 
procedures or cell therapy procedures will not be carried out in this project, nor will laboratory, 
farm or wildlife animals be used. 
10.10  Final report and publication of results 
10.10.1 Final report 
Once the statistical analysis is finished, a final report will be drafted with the results obtained, in 
charge of the Scientific Committee of the Department of Clinical Operations of Sophia Laboratories 
A.S. of V.C. Said report will be prepared following the recommendations of the E3 Step 4 Guide of 
the ICH. 
10.10.2 Communication of results 
Regardless of the results in the study, Sophia Laboratories A.S. of V.C., is committed to communicate 
the final report of the study to the principal investigators and to the corresponding regulatory 
entities of the countries with participating research centers. Maintaining at all times the rights on 
the publication and disclosure of the information contained. 
10.10.3 Publication of the results 
Sophia Laboratories A.S. of V.C., pretending as a sponsor of the study, assumes full responsability 
for its function and retains the exclusive property rights over the results of the study, wich it can use 
in the way it deem convenient.  
The PI undertakes not to publish or communicate data collected only in a center or in part of the 
centers before the publication of the full results of the study, unless prior written agreement is given 
by Sophia Laboratories A.S. of V.C. 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 56 of 65 
 
Any publication and / or communication project related to the study and / or the results obtained 
during the study or after the completion of the study will be presented to participating medical 
researchers at least 30 days in the case of a publication and 15 days in the case of a summary, before 
the scheduled date for the communication and / or presentation of a publication. The medical 
researcher or doctors will comment on the project within 15 days in the case of a publication and 7 
days in the case of a summary, from the date on which the project is received. 
However, in the event that the sponsor is in the process of submitting a patent application on the 
results of the study, the sponsor may delay its publication or communication of the results of the 
study until the date of registration.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11. Bibliographic references 
 
 
 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 57 of 65 
 
[1]  K. Suzuki, J. Saito, Y. R y e. al, «Cell-matrix and cell-cell interactions durong corneal epithelial 
wound healing.,» Progress in Retinal and Eye Research, vol. 22, pp. 113-133, 2003.  
[2]  A. Ljubimov y S. M., «Progress in corneal wound healing,» Progress in Retinal and Eye 
Research, vol. 49, pp. 17-45, 2015.  
[3]  S. Tseng, «Regulation and clinical implications of corneal epithelial stem cells,» Mol Biol Rep, 
vol. 23, pp. 47-58, 1996.  
[4]  C. Brakebusch, D. Bouvard, S. F y e. al., «Integrins in invasive growth.,» J Clin Invest, vol. 109, 
pp. 999-1006, 2002.  
[5]  F. Yu, J. Yin, K. Xu y J. Huang, «Growth factors and corneal epithelial wound healing.,» Brain 
Res Bull, vol. 81, pp. 229-235, 2010.  
[6]  A. Grixti, M. Sadri y M. Watts, «Corneal protection during general anesthesia for nonocular 
surgery,» Ocul Surf, vol. 11, nº 2, pp. 109-118, 2013.  
[7]  S. Tuli, G. Schultz y D. Downer, «Science adn strategy for preventing adn managing corneal 
ulceration,» Ocul Surf, vol. 5, nº 1, pp. 23-39, 2007.  
[8]  S. Wilson, S. Chaurasia y F. Medeiros, «Apoptosis in the initiation, modulation and termination 
of the corneal wound healing response,» Experimental Eye Research, vol. 85, pp. 305-311, 
2007.  
[9]  I. Tsai, C. Hsu, K. Hung, C. Chang y Y. Cheng, «Applications of biomaterials in corneal wound 
healing,» J Chinese Med Associat, vol. 78, pp. 212-217, 2015.  
[10] M. Malafa, C. JE, R. Bowman y R. Rohrich, «Perioperative corneal abrasion: Updated guidelines 
for prevention and management,» Plast Reconstr Surg, vol. 137, nº 5, pp. 790-798, 2016.  
[11] J. Lichter, L. Marr, S. DB y e. al, «A department-of-Anesthesiology based management protocol 
for perioperative corneal abrasions,» Clin Ophthalmol, vol. 9, pp. 1689-1695, 2015.  
[12] S. Wilson y A. Last, «Management of corneal abrasions,» Am Fam Phys, vol. 123, nº 8, pp. 129-
130, 2004.  
[13] J. Wipperman y J. Dorsch, «Evaluation and management of corneal abrasions,» Am Fam Phys, 
vol. 87, nº 2, pp. 114-120, 2013.  
[14] W. H. Organization, «Corneal blindness: a global perspective,» Bulletin of the World Health 
Organization, vol. 79, pp. 214-221, 2001.  
[15] S. Kathry, A. Lewis, O. Schein, O. Tapha, E. Pradhan y J. Katz, «The epidemiology of ocular 
trauma in rural Nepal,» Br J Ophthalmol, vol. 80, pp. 456-460, 2004.  
[16] K. Kampitak, S. Patrasuwan y K. K., «Cost evaluation of corneal ulcer treatment,» J Med Assoc 
Thai, vol. 96, nº 4, pp. 1-4, 2013.  
 
[17] C. Martinelli-Kläy, L. Lunardi, C. Martinelli, T. Lombardi, E. Soares y M. C., «Modulation of MCP-
1, TGF-B1, and a-SMA expressions in granulation tissue of cutaneous wounds treated with 
local vitamin B complex: an experimental study,» Dermatopathology, vol. 1, pp. 98-107, 2014. 
[18] Y. Ibrahim, D. Boase y I. Cree, «Epidemiological characteristics, predisposing factors and 
microbiological profiles of infectious conreal ulcers: the Portsmouth corneal ulcer study,» Br J 
Ophthalmol, vol. 93, pp. 1319-1324, 2009.  
[19] A. C. o. Toxicology, «Final report on the safety assessment of panthenol and pantothenic acid,» 
Journal of the American College of Toxicology, vol. 6, nº 1, pp. 139-162, 1987.  

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 58 of 65 
 
[20] T. Christ, «Treatment of corneal erosion with a new ophthalmic gel containing panthenol,» 
Spektrum Augenheilkd, vol. 8, nº 5, pp. 224-226, 1994.  
[21] M. Göbbels y D. Grob, «Efficacy of dexpanthenol-containing artificial tears (Siccaprotect) in 
the treatment of dry eyes,» Klin Monatsbl Augenheilkd, vol. 209, pp. 84-88, 1996.  
[22] S. Egger, V. Huber-Spitzy, E. Alzner, C. Scholda y V. Vecsei, «Corneal wound healing after 
superficial foreign body injury: vitamin A and dexpanthenol versus a calf blood extract,» 
Ophthalmologica, vol. 213, pp. 246-249, 1999.  
[23] K. Raczynska, B. Iwaszkiewicz-Bilikiewicz, W. Stozkowska y J. Sadlack-Nowicka, «Clinical 
evaluation of provitamin B5 drops and gel for postoperative treatment of corneal and 
conjunctival injuries,» Klin Oczna, vol. 105, nº 3-4, pp. 175-178, 2003.  
[24] K. Raczynska, B. Iwaszkiewicz-Bilikiewicz y W. Stozkowska, «Gel with provitamin B5 applied 
during tests with the Goldmann triple-mirror,» Klin Oczna, vol. 105, nº 3-4, pp. 179-181, 2003. 
[25] M. Smolle, C. Keller, G. Pinggera, M. Deibl, J. Rieder y P. Lirk, «Clear hydro-gel, compared to 
ointment, provides improved eye comfort after brief surgery,» Can J Anesth, vol. 51, nº 2, pp. 
126-129, 2004.  
[26] G. Egorova, T. Mitichkina y A. Shamsudinova, «Corneal protection in contact lens users,» Vestn 
Oftalmol, vol. 130, nº 2, pp. 59-64, 2014.  
[27] I. Corneregel, «Corneregel IPP».  
[28] Bayer, «IPP. Bephanten. Solución oftálmica».  
[29] U. Pharma, «Siccaprotect. IPP».  
[30] H. R, S. C, M. Y y e. al., «Dexpanthenol modulates gene expression in skin wound healing in 
vivo,» Skin Pharmacol Physiol , vol. 25, pp. 241-248, 2012.  
[31] V. Slyshenkov, D. Dymkowska y L. Wojtczak, «Pantothenic acid and pantothenol increase 
biosynthesis of glutathione by boosting cell energetics,» FEBS letters, vol. 569, pp. 169-172, 
2004.  
[32] Y. Toplu, E. Sapmaz, H. Parlakpinar, M. Kelles, M. Kalcioglu, K. Tanbek y A. Kizilay, «The effect 
of dexpanthenol on ototoxicity induced by cisplatin,» Clinical and Experimental 
Otorhinolaryngology, vol. 9, nº 1, pp. 14-20, 2016.  
[33] M. Nakano, C. Lockhart, E. Kelly y A. Rettie, «Ocular cytochrome P450s and transportes: roles 
in disease and endobiotic and xenobiotic disposition,» Drug Metab Rev, vol. early online, pp. 
1-14, 2014.  
[34] A. Al-Ghananeem y P. Crooks, «Phase I and Phase II ocular metabolic avtivities and the role of 
metabolism in ophthalmic prodrug and codrug design and delivery,» Molecules, vol. 12, pp. 
373-388, 2007.  
[35] J. Kanski, Oftalmología Clínica, Barcelona: Elsevier, 2009.  
[36] R. Ralph, «Invest Ophthalmol,» Invest Ophthalmol, vol. 14, nº 4, pp. 299-302, 1975.  
[37] D. Nelson, «Impression citology,» Cornea, vol. 7, pp. 71-81, 1988.  
[38] R. Singh, A. Joseph, T. Umapathy, N. Tint y H. Dua, «Impression cytology of the ocular surface,» 
Br J Ophthalmol, vol. 89, pp. 1655-1659, 2005.  
[39] E. Lopin, T. Deveney y P. Asbell, «Impression cytology: recent advances and applications in dry 
eye disease,» Ocul Surf, vol. 7, nº 2, pp. 93-110, 2009.  

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 59 of 65 
 
[40] E. Haller-Schober, G. Schwantzwer, A. Berghold y e. al, «Evaluating and impressión cytology 
grading system (IC score) in patientes with dry eye syndrome,» Eye, vol. 20, pp. 927-933, 2006. 
[41] M. Michel, W. Sickenberg y H. Pult, «The effectiveness of questionnaires in the determination 
of contact lens induced dry eye,» Ophthal Physiol Opt, vol. 29, pp. 479-486, 2009.  
[42] N. Efron, «Grading scales for contact lens complications,» Ophtalmic Physiol Opt, vol. 18, pp. 
182-186, 1998.  
[43] [En línea].  
[44] International Dry Eye WorkShop 2007, «Methodologies to diagnose and monitor dy eye 
disease,» Ocul Surf, vol. 5, nº 2, pp. 108-152, 2007.  
[45] Secretaría de Salud México, «NORMA Oficial Mexicana NOM-220-SSA1-2012, Instalación y 
operación de la farmacovigilancia.,» Diario Oficial, 2013.  
[46] International Conference on Harmanisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, «Clinical Safety Data Management: Definitions and Standards 
for Expedited Reporting E2A,» ICH Harmonised Tripartite Guideline, vol. 4 version, 1994.  
[47] International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, «General Considerations for Clinical Trials,» ICH Topic E8, 
1998.  
[48] I. Aramendi, L. Ardao, M. Oyarzun, M. Pérez, I. Olmos y M. Frontini, «Problemas relacionados 
con medicamentos en pacientes hospitalizados en el Hospital Vilardebó,» Rev Psiquiatr Urug, 
vol. 75, nº 2, pp. 123-133, 2011.  
 
 
 
 
 
 
 
 
 
[49] R. Meyboom, A. Egberts, I. Edwards, Y. Hekster, F. Koning y Gribnau, «Principles of signal 
detection in pharmacovigilance.,» Drug Safety, vol. 16, pp. 355-365, 1997.  
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 61 of 65 
 
12. Signature page 
Medical manager of the study: 
Dr. Leopoldo Martín Baiza Durán 
Director of the study: 
Dr. Aldo Arturo Oregon Miranda 
Protocol authors: 
Dr. Oscar Olvera Montaño 
Dr. Arieh Roldán Mercado Sesma 
Internal reviewer of the protocol: 
QFB Virginia Manuela Villa Felix 
QFB Jessica Lizette Mejía Gutiérrez 
External reviewer of the protocol: 
  Dr. Mariana Xacil Díaz Salazar 
Principal investigator of the study: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 62 of 65 
 
 
 Page left intentionally blank

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 63 of 65 
 
13. Annexes 
13.1 Eye comfort index 
 
SOPH167-0816-I
/
/
Iniciales del sujeto:
No. de sujeto: 167-______-_______
Indicaciones:
Este cuestionario fue diseñado para calificar el confort de sus ojos.
Para cada pregunta circule su respuesta
Ejemplo:
En la semana pasada, ¿qué tan seguido sus ojos estuvieron rojos?
No existen respuestas correctas o incorrectas. No tome demasiado tiempo en cada pregunta.
1
En la semana pasada, ¿qué tan seguido sus ojos se sintieron secos?
Cuando sus ojos se sentían secos , por lo general, ¿qué tan intensa era la sensación?
2
En la semana pasada, ¿qué tan seguido sus ojos se sintieron arenosos ?
Cuando sus ojos se sentían arenosos , por lo general, ¿qué tan intensa era la sensación?
3
En la semana pasada, ¿qué tan seguido sus ojos sintieron punzadas ?
Cuando sus ojos sentían punzadas , por lo general, ¿qué tan intensa era la sensación?
4
En la semana pasada, ¿qué tan seguido sus ojos se sintieron cansados ?
Cuando sus ojos se sentían cansados , por lo general, ¿qué tan intensa era la sensación?
Hoja 1 de 2
No lo he sentido
Severo
0
1
2
3
4
5
6
No lo he sentido
Nunca
Siempre
0
1
2
3
4
5
6
Severo
0
1
2
3
4
5
6
No lo he sentido
Nunca
Siempre
0
1
2
3
4
5
6
Severo
0
1
2
3
4
5
6
No lo he sentido
Nunca
Siempre
0
1
2
3
4
5
6
6
Siempre
Severo
0
1
2
3
4
5
0
1
2
3
4
5
6
5
6
Nunca
Siempre
Índice de Confort Ocular
Nunca
No. de estudio
Fecha: 
0
1
2
3
4
Ficha de identificación

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 64 of 65 
 
 
5
En la semana pasada, ¿qué tan seguido sus ojos se sintieron adoloridos ?
Cuando sus ojos se sentían adoloridos , por lo general, ¿qué tan intensa era la sensación?
6
En la semana pasada, ¿qué tan seguido sus ojos sintieron comezón ?
Cuando sus ojos sentían comezón , por lo general, ¿qué tan intensa era la sensación?
Nunca
Siempre
0
1
2
3
4
5
6
Severo
0
1
2
3
4
5
6
No lo he sentido
No lo he sentido
Índice de confort ocular
Hoja 2 de 2
Índice de confort ocular, traducido del Ocular Comfort Index disponible en: http://iovs.arvohournals.org
Severo
0
1
2
3
4
5
6
Nunca
Siempre
0
1
2
3
4
5
6

PRO-167 
 
Clinical study protocol: SOPH167-0816 / I 
CONFIDENTIAL                                                               Version: 1.0 
 
Sophia Laboratories A.S. of V.C. 
Page 65 of 65 
 
13.2 Efron scale for conjunctival hyperemia 
 
13.3 Oxford Scale 
 
 
 
Normal 0 
Very slight 1 
mild 2 
Moderate 3 
Severe 4 
Equal or less than panel A 
Equal to or less than panel B, 
greater than A
Equal to or less than panel C, 
greater than B
Equal to or less than panel D, 
greater than C
Equal to or less than panel E, 
greater than D
Greater than panel E
Grade 
Criterion